{"title":"Iron Sucrose Injections","description":"\u003ch1\u003eIron Sucrose Injection – Rapid IV Iron Therapy for Anemia\u003c\/h1\u003e\n\u003cp\u003eIron sucrose is a \u003cstrong\u003epotent intravenous iron infusion\u003c\/strong\u003e (also known by the brand name \u003cem\u003eVenofer\u003c\/em\u003e in the US) formulated as an aqueous complex of polynuclear iron(III)-hydroxide in sucrose. Given by IV injection or slow infusion in a clinic or hospital setting, it \u003cstrong\u003ebypasses the digestive tract\u003c\/strong\u003e and delivers elemental iron directly into the bloodstream. This direct delivery restores body iron stores far more quickly and completely than oral iron tablets, without the stomach upset, constipation or reflux commonly caused by iron pills. In clinical practice, iron sucrose infusions \u003cstrong\u003esignificantly raise hemoglobin levels and ferritin\u003c\/strong\u003e (stored iron) in just days, which relieves anemia symptoms. For example, Dr. Sree Mohana Preetha notes that iron sucrose \u003cem\u003e“replenishes body iron stores”\u003c\/em\u003e especially in kidney failure patients. In contrast to blood transfusion, an iron sucrose infusion is \u003cstrong\u003egen­erally safer and more convenient\u003c\/strong\u003e for chronic iron deficiency. Many patients with fatigue and low energy due to anemia report \u003cstrong\u003eimproved stamina and reduced fatigue\u003c\/strong\u003e within days of treatment.\u003c\/p\u003e\n\u003ch2\u003eWhat is Iron Sucrose and How It Works\u003c\/h2\u003e\n\u003cp\u003eIron sucrose is an FDA-approved \u003cstrong\u003eiron replacement product\u003c\/strong\u003e given by intravenous infusion. In the bloodstream, it dissociates into free iron and sucrose, with the \u003cem\u003ereticuloendothelial system\u003c\/em\u003e breaking down the complex so iron can bind transferrin and be delivered to the bone marrow. There, the iron is incorporated into hemoglobin in developing red blood cells. Each milliliter of iron sucrose solution contains \u003cstrong\u003e20 mg of elemental iron\u003c\/strong\u003e. In practice, it is supplied as 5–10 mL vials (100–200 mg iron) or bags for infusion. Because the iron is water-soluble and stable, the infusion can be given relatively quickly – often \u003cstrong\u003e100–200 mg over 2–5 minutes or 15–30 minutes per session\u003c\/strong\u003e – under a doctor’s supervision.\u003c\/p\u003e\n\u003ch2\u003eIndications \u0026amp; Uses\u003c\/h2\u003e\n\u003cp\u003e• \u003cstrong\u003eIron deficiency anemia (IDA):\u003c\/strong\u003e Iron sucrose is primarily indicated for treating iron-deficiency anemia, especially when rapid correction is needed or oral iron is not effective. It is commonly used in people with chronic kidney disease (CKD), whether or not they are on dialysis. In CKD, anemia often results from both low iron stores and reduced erythropoietin. Iron sucrose quickly raises hemoglobin (Hb) and ferritin to improve oxygen delivery. Guidelines support IV iron for CKD anemia when transferrin saturation (TSAT) is low and ferritin \u0026lt;500 ng\/mL.\u003c\/p\u003e\n\u003cp\u003e• \u003cstrong\u003ePostpartum or Menstrual Anemia:\u003c\/strong\u003e Severe bleeding from childbirth or heavy periods can deplete iron. When hemoglobin is very low or oral supplements can’t keep up, an iron sucrose infusion replenishes iron stores and prevents transfusion.\u003c\/p\u003e\n\u003cp\u003e• \u003cstrong\u003eChronic Fatigue \u0026amp; Low Energy:\u003c\/strong\u003e Patients with fatigue, shortness of breath or “brain fog” from iron-deficiency often see swift relief. As one infusion clinic notes, low iron can cause persistent fatigue and cognitive slowing, which improve as iron stores are restored.\u003c\/p\u003e\n\u003cp\u003e• \u003cstrong\u003eIV Iron as Supplement to Erythropoietin:\u003c\/strong\u003e In anemia of chronic disease (like CKD or cancer), iron sucrose is often given along with erythropoiesis-stimulating agents (ESAs) to boost Hb. It can be used “with or without erythropoietin to raise hemoglobin levels”.\u003c\/p\u003e\n\u003cp\u003e• \u003cstrong\u003eOther Uses (Off-Label):\u003c\/strong\u003e Intravenous iron is sometimes used off-label for anemia in pregnancy (after the first trimester) when oral iron fails, in chemotherapy-induced anemia to reduce transfusions, or in malabsorptive states (e.g. inflammatory bowel disease). Evidence from trials supports iron sucrose in many of these settings.\u003c\/p\u003e\n\u003ch2\u003eTypes of Parenteral Iron Products\u003c\/h2\u003e\n\u003cp\u003eIron sucrose is one of several \u003cstrong\u003eIV iron formulations\u003c\/strong\u003e. Other parenteral irons include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eFerric carboxymaltose (Ferinject\/Injectafer):\u003c\/strong\u003e A high-dose IV iron given in large single doses (up to 750–1000 mg) over 15+ minutes. Favorable for one-visit therapy but requires monitoring for low phosphate.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFerric gluconate (Ferrlecit):\u003c\/strong\u003e Older IV iron used in dialysis; milder infusion, smaller doses (~125 mg) over 10 minutes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIron dextran (Infed\/Dexferrum):\u003c\/strong\u003e First IV iron with larger complexes; higher risk of allergic reaction (test dose often given). Iron sucrose has much lower hypersensitivity risk.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFerumoxytol (Feraheme):\u003c\/strong\u003e Nanoparticle IV iron with two 510 mg doses. Good for oxidative stress reduction but can interfere with MRI scans (iron).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eEach has pros\/cons. Iron sucrose is widely used because of its \u003cstrong\u003eestablished safety and efficacy\u003c\/strong\u003e: it provides effective iron repletion with fewer allergic reactions than iron dextran and it can be given quickly in multiple sessions.\u003c\/p\u003e\n\u003ch2\u003ePopular Brands \u0026amp; Packaging\u003c\/h2\u003e\n\u003cp\u003eThe generic \u003cem\u003eIron Sucrose Injection\u003c\/em\u003e is marketed under various brand names around the world. The \u003cstrong\u003eUS\/Canada brand is Venofer\u003c\/strong\u003e (AbbVie), sold as 100 mg\/5 mL vials (20 mg\/mL). Other international names include \u003cem\u003eNicofer\u003c\/em\u003e, \u003cem\u003eEncifer\u003c\/em\u003e, \u003cem\u003eSuez\u003c\/em\u003e, etc. In India, common brands include Irozorb, Redion, Ferosig, Ferri-Inj, among others. Regardless of name, the concentrations are comparable (usually 20 mg\/mL). Hospitals often stock single-use vials (100 mg\/5 mL) for IV administration.\u003c\/p\u003e\n\u003ch2\u003eDosage Strengths and Administration\u003c\/h2\u003e\n\u003cp\u003eEach 5 mL vial contains \u003cstrong\u003e100 mg of elemental iron\u003c\/strong\u003e (20 mg\/mL). Doses are calculated based on hemoglobin deficit and body weight; common regimens might be 100–200 mg per session, given 1–3 times per week. For example, in hemodialysis patients, 100 mg may be given during each of 5–10 dialysis sessions to reach a total of ~1,000 mg. In non-dialysis patients, larger boluses (200 mg) can be given weekly until stores are replete.\u003c\/p\u003e\n\u003cp\u003eAdministration must be \u003cstrong\u003eintravenous only\u003c\/strong\u003e. The solution is clear or light yellow; it can be injected slowly undiluted (over 2–5 minutes) or diluted in saline and infused. The official guidance is: “Administer Venofer only intravenously by slow injection or infusion... each mL contains 20 mg elemental iron”. For example, 100 mg (5 mL) may be given as a 2–5 minute push, or 200 mg (in 10 mL) over 15–30 minutes. Care is taken to avoid extravasation (leakage) and to rotate infusion sites if multiple doses are needed.\u003c\/p\u003e\n\u003ch2\u003eBenefits\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRapid Hemoglobin Boost:\u003c\/strong\u003e By replenishing iron stores, hemoglobin can rise steadily. Typically, reticulocyte count increases in 5–10 days and Hb climbs over 2–4 weeks. This helps correct anemia faster than oral iron.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRestored Vitality and Energy:\u003c\/strong\u003e Iron is essential for oxygen transport; patients often feel more energetic and mentally alert once iron is restored. Clinics report patients \u003cem\u003e“notice increased stamina and reduced fatigue as iron stores are restored”\u003c\/em\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImproved Cognitive and Cardiac Function:\u003c\/strong\u003e Adequate iron improves oxygen delivery to the heart and brain. Treating iron-deficiency anemia can alleviate symptoms like shortness of breath, palpitations, dizziness, and memory issues.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBetter Iron Stores (Ferritin):\u003c\/strong\u003e IV iron loads both hemoglobin and storage iron (ferritin) more effectively. Sucrose infusions raise ferritin quickly, ensuring long-term availability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAvoids Oral Iron Side Effects:\u003c\/strong\u003e Iron sucrose has no gastrointestinal side effects (nausea, constipation, dark stools) because it bypasses the gut. This makes it suitable for patients with IBS, ulcers or anyone who can’t tolerate pills.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003ePrecautions \u0026amp; Side Effects\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eHypersensitivity:\u003c\/strong\u003e As with all IV iron, allergic or anaphylactic reactions are possible (though rare with sucrose). Guidelines recommend monitoring patients for at least 30 minutes during and after the infusion for rash, itching, wheezing or hypotension. Emergency equipment and epinephrine should be available. Interestingly, iron sucrose has much \u003cstrong\u003elower risk of serious allergy\u003c\/strong\u003e than iron dextran, so no routine test-dose is required.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eBlood Pressure:\u003c\/strong\u003e Iron Sucrose can cause \u003cstrong\u003ehypotension\u003c\/strong\u003e in some patients during infusion. To minimize this, give the dose slowly, avoid overdilution (keep ≥20 mg\/mL as concentrated as recommended, and ensure the patient is resting. Monitor blood pressure and pulse; if severe dizziness or fainting occurs, stop the infusion and treat supportively.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eInfection Risk:\u003c\/strong\u003e Inactive infections (like a cold) should be resolved before infusion; IV iron can transiently increase bacteria growth since iron is a nutrient for microbes. One review found infection rates roughly similar between IV iron and oral or no iron, but clinicians still advise delaying infusion in active systemic infection.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIron Overload:\u003c\/strong\u003e Do NOT use if serum ferritin is already high (e.g. hemochromatosis or hemosiderosis). Over-supplementation can lead to iron overload and organ damage. Monitor labs – ferritin and transferrin saturation – during treatment. Once iron stores are replete (ferritin ~100–500 ng\/mL, TSAT \u0026gt;30%), limit further doses.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOther Contraindications:\u003c\/strong\u003e Avoid IV iron if the patient has non-iron deficiency anemia (e.g. B12 or folate deficiency), unless those are corrected. Also, do not give intramuscularly or subcutaneously (iron sucrose is only for IV use.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSide Effects (Common, ≥2% of patients):\u003c\/strong\u003e These are generally mild and often subside after infusion ends. They include headache, nausea, vomiting, diarrhea, abdominal cramps, dizziness, and injection site pain or burning. Muscle aches, back pain, metallic taste or flushing have also been reported. Post-infusion of iron, some people develop mild joint pain or fever, which usually resolves in a day or two. If side effects occur, slowing the infusion rate or pre-medicating (e.g. acetaminophen) can help.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSpecial Populations:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePregnancy:\u003c\/strong\u003e Iron sucrose is Category C; it crosses the placenta minimally. Animal studies showed no fetal harm, and several reports indicate it's safe in 2nd\/3rd trimester. It is often used to treat severe maternal anemia (which itself risks preterm birth and low birth weight). Most clinicians avoid routine use in the first trimester due to limited data.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBreastfeeding:\u003c\/strong\u003e Very little of the iron passes into breast milk. Oral iron pills are common in lactation, but IV iron sucrose is an option if the mother is severely anemic and intolerant of oral iron.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eElderly:\u003c\/strong\u003e The elderly may be more sensitive to hypotension; dose-escalate carefully and monitor.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePediatrics:\u003c\/strong\u003e Safety in children under 2 years has not been established. For older children, doses are often weight-based but use under expert supervision.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eMonitoring:\u003c\/strong\u003e Check complete blood count, ferritin and TSAT before starting and periodically. Also monitor for injection reactions during infusion (See FDA prescribing info). If multiple doses are given over weeks, monitor hemoglobin weekly and iron studies monthly.\u003c\/p\u003e\n\u003ch2\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRapid Anemia Relief:\u003c\/strong\u003e Iron Sucrose is a “\u003cstrong\u003efast IV iron infusion\u003c\/strong\u003e” that quickly restores iron levels in patients with iron deficiency anemia.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOvercomes Oral Iron Limits:\u003c\/strong\u003e It’s ideal for \u003cstrong\u003eiron-deficiency anemia\u003c\/strong\u003e when pills fail (due to poor absorption or GI side effects). Clinics highlight that it replenishes stores “\u003cstrong\u003efaster and more completely than oral supplements\u003c\/strong\u003e”, helping patients regain energy and vitality.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCommon Uses:\u003c\/strong\u003e Treatment of anemia in chronic kidney disease (dialysis and non-dialysis) chemotherapy-associated anemia, postpartum anemia, heavy menstrual bleeding, and other cases of severe iron deficiency.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdministration:\u003c\/strong\u003e Given \u003cstrong\u003eintravenously by a healthcare professional\u003c\/strong\u003e, usually as 100–200 mg doses (1–5 mL) slowly injected or infused. It’s performed in a clinic or hospital infusion center.\u003c\/li\u003e\n\u003cli\u003e\u003cspan class=\"VODHU pdMy8\"\u003e\u003cstrong\u003eBrands:\u003c\/strong\u003e Often known as \u003cstrong\u003eVenofer\u003c\/strong\u003e, but sold globally under many names (Nicofer, Encifer, Suez, etc\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePrecautions:\u003c\/strong\u003e Not for people with iron overload or active infection. Monitor vital signs for hypotension and allergic reactions during infusion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSide Effects:\u003c\/strong\u003e May include headache, nausea, vomiting, diarrhea, dizziness, muscle cramps, back pain, and injection site itching or pain. These are usually mild and transient.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOutcomes:\u003c\/strong\u003e Many patients report \u003cstrong\u003eless fatigue and more energy\u003c\/strong\u003e after treatment. By boosting hemoglobin, iron sucrose improves oxygen delivery, which can enhance mental focus, exercise tolerance and overall wellness.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn summary, Iron Sucrose is a \u003cstrong\u003ehighly effective IV iron therapy\u003c\/strong\u003e for severe anemia and iron deficiency. It works by \u003cem\u003erapidly repleting iron stores and raising hemoglobin\u003c\/em\u003e, which translates to better energy levels, improved organ function, and avoidance of blood transfusions. Proper patient selection, dosing, and monitoring ensure it provides maximum benefit with minimal side effects.\u003c\/p\u003e","products":[{"product_id":"injectafer-ferric-carboxymaltose-injection-treat-iron-deficiency-anemia","title":"Injectafer Infusion (Ferric Carboxymaltose) 750 mg\/15mL Vial","description":"\u003ch1\u003eInjectafer (Ferric Carboxymaltose) – 750 mg\/15 mL\u003c\/h1\u003e\n\u003cp\u003eInjectafer is an \u003cstrong\u003eintravenous iron replacement\u003c\/strong\u003e therapy (ferric carboxymaltose) used to treat iron deficiency. Each 15 mL vial contains 750 mg elemental iron (50 mg\/mL). Ferric carboxymaltose is a large, polynuclear iron(III)-carbohydrate complex; it is a stable, non-dextran formulation that delivers iron to the body without releasing large amounts of free iron.\u003c\/p\u003e\n\u003ch2\u003eIndications\u003c\/h2\u003e\n\u003cp\u003eInjectafer is indicated for iron deficiency in the following situations (per U.S. prescribing information):\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIron Deficiency Anemia (IDA):\u003c\/strong\u003e Adults and pediatric patients ≥1 year old who are intolerant of, or have an unsatisfactory response to, oral iron).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eChronic Kidney Disease (non-dialysis):\u003c\/strong\u003e Adult patients with IDA and non-dialysis-dependent chronic kidney disease.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHeart Failure:\u003c\/strong\u003e Adult patients with iron deficiency (with or without anemia) and NYHA class II\/III heart failure, to improve exercise capacity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eDosage and Administration\u003c\/h2\u003e\n\u003cp\u003eInjectafer is administered \u003cstrong\u003eintravenously\u003c\/strong\u003e by slow infusion or injection only. Recommended dosing (per treatment course) is weight-based:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePatients ≥50 kg:\u003c\/strong\u003e 750 mg IV (15 mL) \u003cem\u003etwice\u003c\/em\u003e, given on two occasions at least 7 days apart (total 1500 mg iron per course) As an alternative, a single 15 mg\/kg dose (up to 1000 mg) may be given for adults ≥50 kg.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePatients \u0026lt;50 kg:\u003c\/strong\u003e 15 mg\/kg IV (maximum 750 mg) on two occasions at least 7 days apart (total ≤1500 mg iron per course).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eMaximum single dose:\u003c\/strong\u003e 750 mg of iron (i.e. one vial).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eMaximum per course:\u003c\/strong\u003e 1500 mg of iron (over the two doses).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor administration, the 750 mg dose may be diluted (e.g. in ≤250 mL normal saline) and infused over ≥15 minutes. It can also be given by slow IV push (≈100 mg\/min) if undiluted. Patients must be monitored during and for at least 30 minutes after each infusion for signs of hypersensitivity, with resuscitation equipment available. If iron deficiency anemia recurs, a repeat course may be given under the same guidelines.\u003c\/p\u003e\n\u003ch2\u003eAdverse Reactions and Precautions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eHypersensitivity:\u003c\/strong\u003e Serious allergic reactions (including anaphylaxis) can occur. Monitor patients for ≥30 minutes after infusion and ensure emergency treatment (e.g. epinephrine) is available. Contraindicated in anyone with a history of hypersensitivity to Injectafer or its components.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCommon side effects:\u003c\/strong\u003e In adults (\u0026gt;2%), most often nausea, transient hypertension, flushing, injection-site reactions (pain, erythema), hypophosphatemia, and dizziness. In pediatric patients, common effects include hypophosphatemia, injection-site reactions, rash, headache, and vomiting.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHypophosphatemia:\u003c\/strong\u003e IV iron can lower serum phosphate. Repeat courses of Injectafer frequently cause transient hypophosphatemia; monitor phosphate in patients at risk. \u003cstrong\u003eBlood pressure:\u003c\/strong\u003e Transient hypertension can occur; monitor blood pressure during\/after infusion\u003c\/p\u003e\n\u003cp\u003eOther considerations: \u003cstrong\u003eNot for anemia of other causes\u003c\/strong\u003e (oxygenation or B12 deficiency, etc.). Avoid overdose, as iron overload (hemosiderosis) can result. Caution in patients with active infection (bacteria thrive on iron). Patients should be advised to report any symptoms of allergy (rash, itching, dizziness, breathing difficulty, swelling) immediately.\u003c\/p\u003e\n\u003ch2\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp\u003eFerric carboxymaltose is a \u003cstrong\u003estable iron complex\u003c\/strong\u003e; after IV administration, iron is slowly released and taken up by macrophages in the reticuloendothelial system. The iron is then incorporated into ferritin and hemoglobin. The stability of the carboxymaltose shell minimizes free iron release and reduces oxidative stress compared to older iron dextrans.\u003c\/p\u003e","brand":"American Regent","offers":[{"title":"Default Title","offer_id":12112212066376,"sku":"00517-0650-01","price":2250.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Injectafer-_Ferric-Carboxymaltose_-Injection-750-mg-by-American-Regent-00517-0650-01.jpg?v=1747922875"},{"product_id":"infed-iron-dextran-complex-50-mg-for-injection-single-dose-vials-2-ml","title":"INFeD Iron Dextran Injection 50 mg Single Dose Vials 2 mL (RX)","description":"\u003cp\u003eINFeD (Iron Dextran Complex) 50 mg is an injectable medication used to treat iron deficiency anemia when oral iron supplements are ineffective or cannot be used. It works by replenishing iron stores in the body, which is essential for producing hemoglobin and healthy red blood cells. INFeD is typically administered under the supervision of a healthcare professional, and the dosage is determined based on the patient's specific needs and condition.\u003c\/p\u003e\n\u003cp\u003eIron dextran is a complex of iron and the sugar dextran. When injected into the body, it is broken down into iron and dextran molecules. The iron component is then transported to the bone marrow, where it is used to produce hemoglobin, the protein in red blood cells that carries oxygen.\u003c\/p\u003e\n\u003cp\u003eIn individuals with iron deficiency anemia, there is a lack of iron available for red blood cell production. This can be due to insufficient dietary intake of iron, poor absorption of iron from the diet, or increased demands for iron (such as during pregnancy). By providing a source of iron directly into the body, INFeD helps to correct the iron deficiency and increase the production of red blood cells.\u003c\/p\u003e\n\u003cp\u003eINFeD is typically given as an injection into a muscle or vein and is usually prescribed for several weeks to replenish iron stores and improve anemia symptoms. It is important to continue taking iron supplements or consuming iron-rich foods, as INFeD only provides a temporary boost of iron and does not address the underlying cause of iron deficiency.\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eProduct Details and Features:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eEffective Iron Supplementation:\u003c\/strong\u003e Each 2 mL vial contains 50 mg of elemental iron, designed to address iron deficiency anemia efficiently.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eParenteral Administration:\u003c\/strong\u003e Offers an alternative for patients unable to tolerate oral iron supplements.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSingle-Dose Vials:\u003c\/strong\u003e Convenient packaging ensures accurate dosing and reduces the risk of contamination.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTrusted Manufacturer:\u003c\/strong\u003e Produced by Allergan Pharmaceuticals, guaranteeing quality and reliability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism of Action:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eINFeD Iron Dextran Complex works by providing elemental iron directly into the bloodstream, bypassing the gastrointestinal tract. This allows for rapid replenishment of iron stores, facilitating the production of hemoglobin and red blood cells, thus improving oxygen transport and energy levels.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDirections for Use:\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePreparation:\u003c\/strong\u003e Inspect the vial for any particulate matter or discoloration prior to use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eAdministration:\u003c\/strong\u003e Administer as an intravenous infusion or intramuscular injection as per healthcare provider instructions. Ensure proper aseptic technique.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eDosage:\u003c\/strong\u003e Follow the prescribed dosage regimen by your healthcare provider.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eAftercare:\u003c\/strong\u003e Monitor the patient post-infusion or injection for any adverse reactions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cstrong\u003eWarnings:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOnly to be administered under the supervision of a healthcare professional.\u003c\/li\u003e\n\u003cli\u003ePatients with a known hypersensitivity to iron dextran should not use this product.\u003c\/li\u003e\n\u003cli\u003eConduct a test dose prior to administering a full dose to assess potential allergic reactions.\u003c\/li\u003e\n\u003cli\u003eUse with caution in patients with a history of allergies or asthma.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eSide Effects:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCommon side effects may include pain at the injection site, headache, dizziness, nausea, or flushing.\u003c\/li\u003e\n\u003cli\u003eSerious side effects can occur, such as anaphylactic reactions, hypotension, or severe dizziness. Immediate medical attention is required in such cases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eChoose INFeD Iron Dextran Complex for a reliable and trusted solution to managing iron deficiency anemia, ensuring the highest standards of care and efficacy for your patients.\u003c\/p\u003e","brand":"Allergan Pharmaceuticals","offers":[{"title":"Default Title","offer_id":40351704055880,"sku":"00023-6082-10","price":623.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/INFeD-Iron-Dextran-Complex-50-mg-for-Injection.jpg?v=1720721297"},{"product_id":"ferumoxytol-injection-iron-replacement-medication","title":"Ferumoxytol Injection Iron Replacement 510 mg Single-Dose Vial 17 mL (RX)","description":"Ferumoxytol (brand name Feraheme) is an intravenous iron therapy used to treat iron deficiency anemia in adults. It is given as an injection in a healthcare setting, usually administered in two separate doses spaced a few days apart.\n\u003cp\u003eFerumoxytol Injection by Sandoz is a high-potency intravenous iron replacement medication, supplied as a 30 mg\/mL solution in a convenient 17 mL single-dose vial. Designed for healthcare professionals, Ferumoxytol provides rapid and effective treatment of iron deficiency anemia (IDA), particularly in adult patients with chronic kidney disease (CKD) or when oral iron therapy is ineffective or not tolerated.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eWhat is Ferumoxytol Used For?\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eFerumoxytol Injection is indicated for:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTreatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD), including those on dialysis and non-dialysis-dependent.\u003c\/li\u003e\n\u003cli\u003ePatients who cannot tolerate oral iron supplements or for whom they have proven ineffective.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cstrong\u003eCDC Guidelines and Recommendations\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eThe Centers for Disease Control and Prevention (CDC) recommend intravenous iron supplementation for CKD patients with iron deficiency anemia, particularly when oral iron is insufficient.\u003c\/li\u003e\n\u003cli\u003eIntravenous iron therapy, such as ferumoxytol, is endorsed to quickly restore iron stores, improve hemoglobin levels, and reduce symptoms related to anemia (CDC Chronic Kidney Disease Surveillance System).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cstrong\u003eDosage \u0026amp; Administration\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eStandard Adult Dosage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEach vial contains 510 mg of elemental iron (30 mg\/mL x 17 mL).\u003c\/li\u003e\n\u003cli\u003eRecommended dose: two separate IV injections of 510 mg each, administered over at least 15 minutes, 3 to 8 days apart (total cumulative dosage: 1,020 mg).\u003c\/li\u003e\n\u003cli\u003eDosage and frequency should be determined by the prescribing healthcare provider based on individual patient needs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cstrong\u003eDetails and Features\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eContent:\u003c\/strong\u003e 30 mg\/mL elemental iron, 17 mL per single-use vial.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNDC:\u003c\/strong\u003e 00781-3154-01\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBrand:\u003c\/strong\u003e Sandoz, a trusted pharmaceutical supplier.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Stable, ready-to-use injectable solution.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdministration:\u003c\/strong\u003e Intravenously, under professional medical supervision.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cstrong\u003eMechanism of Action\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eFerumoxytol consists of a superparamagnetic iron oxide core surrounded by a carbohydrate shell, allowing for controlled release of iron into the body. The released iron is rapidly incorporated into hemoglobin and other essential iron-dependent proteins, quickly correcting iron deficiency and enabling efficient erythropoiesis (red blood cell production).\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eDirections for Use\u003c\/strong\u003e\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003eInspect vial for particulate matter or discoloration prior to use.\u003c\/li\u003e\n\u003cli\u003eDo not dilute or mix with other medications.\u003c\/li\u003e\n\u003cli\u003eAdminister via IV injection or infusion, as directed by a healthcare professional.\u003c\/li\u003e\n\u003cli\u003eEach dose should be given slowly, over at least 15 minutes, to reduce the risk of adverse reactions.\u003c\/li\u003e\n\u003cli\u003eMonitor patient closely during and after administration for any signs of hypersensitivity.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch3\u003e\u003cstrong\u003eImportant Warnings\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypersensitivity Reactions:\u003c\/strong\u003e Serious, potentially fatal hypersensitivity reactions, including anaphylaxis, have occurred. Patients should be monitored during and for at least 30 minutes after administration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypotension:\u003c\/strong\u003e Monitor blood pressure, as a drop in blood pressure can occur following administration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIron Overload:\u003c\/strong\u003e Evaluate iron parameters before each dose; avoid in patients with evidence of iron overload.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eUse in Pregnancy:\u003c\/strong\u003e Limited data available; consult physician prior to use if pregnant or breastfeeding.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cstrong\u003ePotential Side Effects\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eThe most common adverse reactions include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNausea\u003c\/li\u003e\n\u003cli\u003eDizziness\u003c\/li\u003e\n\u003cli\u003eHypotension (low blood pressure)\u003c\/li\u003e\n\u003cli\u003eDiarrhea\u003c\/li\u003e\n\u003cli\u003eHeadache\u003c\/li\u003e\n\u003cli\u003eFlushing\u003c\/li\u003e\n\u003cli\u003eEdema\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eSerious Side Effects:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHypersensitivity reactions such as rash, urticaria, chest pain, or swelling of the face\/lips\/throat require immediate medical attention.\u003c\/li\u003e\n\u003cli\u003eSevere hypotension, which may require cardiovascular support.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eStore at controlled room temperature (20° to 25°C or 68° to 77°F).\u003c\/li\u003e\n\u003cli\u003eDo not freeze or expose to extreme heat.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eFerumoxytol Injection by Sandoz\u003c\/strong\u003e offers a safe, efficient, and reliable solution for rapid iron repletion in adults with chronic kidney disease or those who cannot tolerate oral iron, helping to restore energy, reduce anemia symptoms, and improve quality of life under proper medical supervision.\u003c\/p\u003e\n\u003cp\u003eFor complete prescribing information, always refer to the official product monograph or consult your healthcare provider.\u003c\/p\u003e","brand":"Sandoz","offers":[{"title":"Default Title","offer_id":52295749402992,"sku":"00781-3154-01","price":599.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Ferumoxytol-Injection-Iron-Replacement-Sandoz.jpg?v=1767359129"},{"product_id":"iron-sucrose-injection-200-mg-elemental-iron-per-10-ml-single-dose-vial","title":"Iron Sucrose Injection 200 mg Elemental Iron 10 mL Single-Dose Vial (RX)","description":"\u003ch1\u003eIron Sucrose (Venofer) – Intravenous iron replacement therapy\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003eIron sucrose\u003c\/strong\u003e (brand name \u003cstrong\u003eVenofer\u003c\/strong\u003e among others) is an \u003cstrong\u003eintravenous iron replacement\u003c\/strong\u003e medication used to treat iron-deficiency anemia. It is most commonly given to patients who cannot absorb or tolerate oral iron or who have chronic kidney disease (CKD) causing anemia. Iron sucrose is supplied as a liquid solution and is given by a healthcare provider into a vein. The infusion is administered slowly (typically over 2–5 minutes or up to a few hours, depending on dose) with careful medical supervision. Because serious allergic or cardiopulmonary reactions are possible (though uncommon), patients are watched closely during and for at least 30 minutes after the infusion.\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003e\u003cstrong\u003eMechanism:\u003c\/strong\u003e Iron sucrose works by \u003cstrong\u003ereplenishing the body’s iron stores\u003c\/strong\u003e, allowing the bone marrow to make more hemoglobin and red blood cells. It is a complex of iron and sucrose; once infused, the iron is released and used to build hemoglobin in red cells. (In other words, it restores iron so the blood can carry more oxygen.)\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003e\u003cstrong\u003eAdministration:\u003c\/strong\u003e This is a \u003cstrong\u003eprescription-only\u003c\/strong\u003e injection administered in a medical setting by a doctor or nurse. It is given by slow intravenous infusion or injection (typically over several minutes). For example, common vial strengths are 50 mg (2.5 mL) or 100 mg (5 mL) of iron per dose (20 mg\/mL concentration). A series of infusions (e.g. 100–200 mg each session) is usually given until iron levels are restored.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003e\u003cstrong\u003ePrecautions\/Safety:\u003c\/strong\u003e Iron sucrose infusions must be given under medical supervision. Rapid infusions can cause side effects such as low blood pressure or allergic reactions, so vital signs are monitored during and after the dose. Because of this, patients are observed for at least 30 minutes after each infusion. It should \u003cem\u003enot\u003c\/em\u003e be used in patients with iron overload (hemochromatosis) or known hypersensitivity to iron sucrose.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eDiscover the powerful benefits of \u003cstrong\u003eIron Sucrose Injection 200 mg Elemental Iron Per 10 mL Single-Dose Vial\u003c\/strong\u003e by Sandoz, a trusted solution for the safe and effective treatment of \u003cstrong\u003eiron deficiency anemia (IDA)\u003c\/strong\u003e. Backed by high efficacy and patient safety, this injectable \u003cstrong\u003eIV iron supplement\u003c\/strong\u003e delivers vital iron directly to your bloodstream, rapidly improving iron levels, increasing hemoglobin, and combatting fatigue, weakness, and other symptoms related to iron deficiency or chronic kidney disease (CKD).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eExperience rapid and reliable anemia treatment with Iron Sucrose Injection 200 mg Elemental Iron per 10 mL Single-Dose Vial by Sandoz. This top-rated, hospital-grade intravenous iron supplement is clinically proven to effectively treat iron deficiency anemia and replenish vital iron stores, providing fast relief from fatigue, weakness, and other anemia symptoms. Designed for highest efficacy, this IV iron therapy delivers 200 mg of elemental iron per single-dose vial, ideal for patients who are unable to tolerate or have an inadequate response to oral iron supplements. Sandoz, a global leader in pharmaceuticals, guarantees superior quality, purity, and safety in every vial.\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eUses\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eIron Sucrose Injection\u003c\/strong\u003e is primarily used in:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTreatment of \u003cstrong\u003eiron deficiency anemia\u003c\/strong\u003e (IDA), especially in patients with chronic kidney disease (CKD)\u003c\/li\u003e\n\u003cli\u003ePatients who have intolerance or unresponsiveness to oral iron supplements\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHemodialysis\u003c\/strong\u003e and \u003cstrong\u003eperitoneal dialysis\u003c\/strong\u003e patients requiring intravenous iron replacement\u003c\/li\u003e\n\u003cli\u003eHospital and clinical settings for fast iron repletion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cstrong\u003eWhat Is Iron Sucrose?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eIron Sucrose\u003c\/strong\u003e is an intravenous iron replacement product containing \u003cstrong\u003eelemental iron\u003c\/strong\u003e complexed with sucrose. It’s designed for rapid and efficient correction of \u003cstrong\u003eiron deficiency\u003c\/strong\u003e when oral supplements are inadequate or not tolerated. Sandoz is a leading manufacturer, guaranteeing pharmaceutical-grade quality.\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eWhat Is Anemia?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eAnemia\u003c\/strong\u003e is a medical condition characterized by a deficiency in the number or quality of red blood cells or hemoglobin, resulting in insufficient oxygen transport in the blood. The most common cause is \u003cstrong\u003eiron deficiency\u003c\/strong\u003e, which leads to symptoms like fatigue, weakness, shortness of breath, dizziness, pale skin, and reduced immune function. Correcting the iron deficit is crucial for restoring health and vitality.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eHow It Works:\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eIron Sucrose Injection delivers elemental iron directly into the bloodstream, allowing quick and efficient utilization by the body for hemoglobin production and oxygen transport. This is especially essential for patients with restricted oral absorption, gastrointestinal upset, or those undergoing chronic hemodialysis.\u003c\/p\u003e\n\u003cp\u003eWith \u003cstrong\u003eIron Sucrose Injection 200 mg by Sandoz\u003c\/strong\u003e, you receive rapid, reliable, and safe iron repletion—ideal for patients who require swift correction of anemia, superior tolerability, and minimal side effects. Trusted by healthcare professionals worldwide, Sandoz ensures pharmaceutical excellence, patient safety, and compliance with all regulatory standards.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRestore vitality, treat anemia promptly, and promote overall well-being with Sandoz Iron Sucrose today!\u003c\/strong\u003e\u003c\/p\u003e","brand":"Sandoz","offers":[{"title":"Default Title","offer_id":52703763923312,"sku":"00781-3487-94","price":129.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Iron-Sucrose-Injection-200-mg-Sandoz-00781-3487-94.jpg?v=1764858737"},{"product_id":"iron-sucrose-injection-20-mg-ml-single-dose-vial-2-5-ml-x-10-pack-rx","title":"Iron Sucrose Injection 20 mg\/mL SIngle-Dose Vial 2.5 mL x 10\/Pack (RX)","description":"\u003ch1\u003eIron Sucrose Injection\u003c\/h1\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003e Iron sucrose injection (20 mg\/mL, 2.5 mL single-dose vial) is an \u003cstrong\u003eintravenous iron replacement\u003c\/strong\u003e product marketed by International Medication Systems, Limited (IMS). Each 2.5 mL vial contains 50 mg elemental iron as iron(III)-hydroxide sucrose complex (20 mg\/mL). The vial is preservative-free and intended for single use only – any unused portion must be discarded. This IMS formulation is a generic equivalent of branded iron sucrose products (e.g. Venofer®). It is used only by prescription, under medical supervision. Iron sucrose injection is \u003cstrong\u003efor intravenous use only\u003c\/strong\u003e (via slow IV injection or infusion), and \u003cstrong\u003enot given intramuscularly or orally\u003c\/strong\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\n\u003cspan class=\"VODHU pdMy8\"\u003eMechanism of Action\u003c\/span\u003e:\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eIron sucrose is a complex of polynuclear iron(III)-hydroxide in a sucrose shell. After IV administration, the complex dissociates: iron is released and binds transferrin in the blood. Transferrin carries iron to the bone marrow and other target tissues. In erythroid precursor cells, the delivered iron is incorporated into hemoglobin and new red blood cells. Excess iron is stored in liver, spleen and bone marrow until needed. The sucrose moiety is largely excreted unchanged by the kidneys. Because it delivers iron directly to the bloodstream, iron sucrose promptly raises serum iron and ferritin levels, improving anemia where oral iron cannot suffice.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eIndications:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eBy label [IMS and FDA], iron sucrose injections are \u003cstrong\u003eindicated for treatment of iron-deficiency anemia (IDA) in patients with chronic kidney disease (CKD)\u003c\/strong\u003e. This includes adult and pediatric CKD patients on hemodialysis, peritoneal dialysis, or those not yet on dialysis. The efficacy in CKD is well established: iron sucrose is given along with erythropoiesis-stimulating agents (ESAs) to help achieve target hemoglobin levels. (In practice, intravenous iron is preferred in CKD because these patients often have ongoing blood losses, inflammation, or poor oral absorption.)\u003c\/p\u003e\n\u003cp\u003eIron sucrose is also used \u003cem\u003eoff-label\u003c\/em\u003e for other severe iron-deficiency states. For example, it is commonly given for iron-deficiency anemia in \u003cstrong\u003epregnancy or postpartum\u003c\/strong\u003e when oral iron fails or is not tolerated, or in cases of heavy uterine bleeding. It is sometimes used for anemia in inflammatory bowel disease, celiac disease, bariatric surgery, or any condition causing malabsorption, and in cancer patients on chemotherapy. Expert guidelines (e.g. American Society of Hematology) advise using intravenous iron when oral therapy is intolerable or too slow – such as moderate-to-severe anemia or when a quick correction is needed. Some clinicians use IV iron to avert blood transfusions. However, outside CKD such use is “off-label” and should follow clinical judgment. (Notably, major pediatric societies and obstetric guidelines emphasize checking for iron deficiency in these contexts and treating it, often recommending IV iron if oral fails, despite official label being CKD-only.)\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eDosage and Administration:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eIron sucrose is supplied in single-dose vials of 2.5 mL (50 mg), 5 mL (100 mg), and 10 mL (200 mg), all at 20 mg\/mL. Dilution is done only with 0.9% sodium chloride. The final concentration should be 1–2 mg iron\/mL (no less than 1 mg\/mL) if dilution is needed. Do \u003cstrong\u003enot\u003c\/strong\u003e mix with other IV drugs or dextrose – use a dedicated line.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eAdministration: \u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003e Iron sucrose must be infused or injected \u003cstrong\u003eslowly\u003c\/strong\u003e to minimize reactions. For \u003cem\u003ehemodialysis-dependent CKD (HDD-CKD)\u003c\/em\u003e, a common regimen is 100 mg IV at each dialysis (3 times weekly) until ~1000 mg total is given. Each 100 mg dose can be given as a 2–5 minute IV push or a 15-minute infusion (diluted to ≤100 mL saline); it is often administered early in the dialysis session. For \u003cem\u003enon-dialysis CKD (NDD-CKD)\u003c\/em\u003e, typical dosing is 200 mg IV per dose, given \u003cstrong\u003efive times over 2 weeks\u003c\/strong\u003e (e.g. 200 mg on days 1, 4, 7, 10, 13; total 1000 mg). The 200 mg doses can be given as IV push (2–5 minutes) or 15-minute infusions (diluted in ≤100 mL). In some protocols, a 500 mg infusion over ~4 hours on Day 1 and Day 14 has been used, though this is less common. For \u003cem\u003eperitoneal dialysis (PDD-CKD)\u003c\/em\u003e, the usual course is three doses over ~4 weeks: 300 mg IV (over 1.5 h) on day 1 and day 15, then 400 mg IV (over 2.5 h) on day 29 (total 1000 mg) . Again, dilute each dose in ≤250 mL saline. Iron sucrose therapy may be repeated if anemia recurs after completion of a course.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eFor pediatric patients (≥2 years old) on dialysis receiving ESAs, iron maintenance dosing studied was \u003cstrong\u003e0.5 mg\/kg IV (max 100 mg)\u003c\/strong\u003e every 2–4 weeks). (This was shown to maintain hemoglobin in many children.) Iron sucrose is \u003cstrong\u003enot established for initial anemia correction in children\u003c\/strong\u003e (except in CKD\/ESA context). It has been given in some pediatric CKD cases for maintenance. It has not been studied in infants under 2 years, and caution is warranted there. In very low-birthweight neonates (premature \u0026lt;1250 g), there are case reports of necrotizing enterocolitis temporally associated with IV iron; causal relation is unclear, but it underscores caution in infant.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eContraindications: \u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eIron sucrose injection should not be used in any patient with known hypersensitivity\/allergy to iron sucrose or any component (sucrose, etc.). Also avoid use in patients with iron overload (e.g. hemochromatosis or very high ferritin\/TSAT) because excess iron can cause tissue damage.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eWarnings\/Precautions:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eThe most serious risks are \u003cstrong\u003ehypersensitivity reactions\u003c\/strong\u003e and \u003cstrong\u003ehypotension\u003c\/strong\u003e. Acute allergic\/anaphylactic reactions (flushing, wheezing, hypotension, shock, severe rash or swelling) have been reported, though less commonly with iron sucrose than older iron dextrans. Always administer IV iron sucrose in a setting where resuscitation is available. Observe the patient during and for ≥30 minutes after each infusion for signs of allergy. If bronchospasm or anaphylaxis occur, stop the infusion immediately and treat (epinephrine, IV fluids, etc.). Patients with a history of asthma, atopy, or previous reactions to iron are higher risk.\u003c\/p\u003e\n\u003cp\u003eIron sucrose can cause \u003cstrong\u003ehypotension\u003c\/strong\u003e if infused too rapidly or in sensitive patients. To minimize this, infuse slowly and monitor blood pressure. If significant hypotension or syncope occurs, stop infusion, put patient supine, and give IV fluids. (Note: severe maternal hypotension in pregnancy could secondarily compromise fetal perfusion, so extra vigilance is needed obstetrically.)\u003c\/p\u003e\n\u003cp\u003eChronic overuse can lead to \u003cstrong\u003eiron overload (hemosiderosis)\u003c\/strong\u003e. Iron is not easily excreted, so repeated IV dosing can accumulate. Check serum ferritin and transferrin saturation (TSAT) periodically during therapy. Do \u003cem\u003enot\u003c\/em\u003e give additional iron if ferritin is very high (typically \u0026gt;500–1000 ng\/mL) or TSAT exceeds 50%. Maintain target hemoglobin levels and stop iron when stores are adequate.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cspan class=\"VODHU pdMy8\"\u003eSide Effects\u003c\/span\u003e:\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eCommon adverse effects include \u003cstrong\u003egastrointestinal symptoms\u003c\/strong\u003e (nausea, vomiting, diarrhea, constipation) and \u003cstrong\u003eCNS symptoms\u003c\/strong\u003e (headache, dizziness). Other frequent reactions are \u003cstrong\u003ehypotension\u003c\/strong\u003e (often mild or asymptomatic), \u003cstrong\u003emusculoskeletal pain\u003c\/strong\u003e (cramps, arthralgia, back pain), \u003cstrong\u003eflushing\/itching or skin rash\u003c\/strong\u003e (pruritus), and \u003cstrong\u003einjection site reactions\u003c\/strong\u003e. Chest pain or hypertension may also occur These are generally transient. Serious side effects are rare but include severe allergy or shock, and very rarely serious cardiac or renal events if iron is given too rapidly. Patients should report any dyspnea, chest discomfort, or extensive rash during infusion.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003ePregnancy:\u003c\/h2\u003e\n\u003cp\u003eIron sucrose is rated \u003cstrong\u003eCategory B\u003c\/strong\u003e (no evidence of harm in animal studies). Studies of IV iron sucrose \u003cem\u003eafter\u003c\/em\u003e the first trimester have not shown increased risk of birth defects. Data in the first trimester are limited, so it is usually reserved for second\/third trimester unless anemia is severe and cannot be delayed. Importantly, \u003cstrong\u003euntreated iron-deficiency anemia in pregnancy carries risks\u003c\/strong\u003e (premature delivery, low birth weight, maternal morbidity), so treating significant IDA is recommended (often after 12 weeks if oral fails). IMS labeling notes that pregnant women have not shown adverse outcomes when treated in later pregnancy. However, if a severe infusion reaction occurs (hypotension, anaphylaxis), maternal hypotension could harm the fetus, so maternal vitals and fetal heart rate should be monitored as needed.\u003c\/p\u003e\n\u003ch2\u003eLactation:\u003c\/h2\u003e\n\u003cp\u003eIron sucrose does pass into breast milk, but published data show \u003cstrong\u003eno reported adverse effects in breastfed infants\u003c\/strong\u003e (e.g. in women who received 100–300 mg IV iron). There is no clear effect on milk production. Since iron is naturally present in milk, incidental increases seem well tolerated. If needed, IV iron can be used during breastfeeding. Still, consider benefits of breastfeeding and the mother’s anemia.\u003c\/p\u003e\n\u003ch2\u003ePediatrics:\u003c\/h2\u003e\n\u003cp\u003eSee “Dosage” above. IMS labels note that initial treatment safety\/efficacy in children (\u0026lt;2 years) is not established. Only maintenance doses (with ESAs in CKD) have been formally studied in children ≥2 years Premature infants or very young children should generally avoid IV iron unless in exceptional cases (due to possible risk of gut necrosis.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGeriatrics:\u003c\/strong\u003e Trials included many elderly patients, and no age-specific toxicity was noted. Dosing adjustments are usually not needed based on age alone, but monitor for comorbidities (renal, cardiovascular) that could increase sensitivity.\u003c\/p\u003e\n\u003ch2\u003eDrug Interactions:\u003c\/h2\u003e\n\u003cp\u003eBecause iron sucrose is given IV, it bypasses gut absorption. Thus \u003cstrong\u003eoral drug interactions\u003c\/strong\u003e (e.g. diminished absorption of oral quinolone antibiotics or levodopa) are not relevant. However, do \u003cstrong\u003enot mix\u003c\/strong\u003e iron sucrose in the same IV line with other drugs (especially those containing sulfhydryl or alkaline reduce valency) because the iron complex can bind or precipitate. There are no major CYP-related interactions. In general, treatment can proceed without altering other medications, but monitor for additive blood pressure effects if the patient is on antihypertensives or anesthesia.\u003c\/p\u003e\n\u003ch2\u003eOverdose:\u003c\/h2\u003e\n\u003cp\u003eAcute overdose of IV iron (beyond recommended doses) can lead to iron toxicity: severe hypotension, metabolic acidosis, gastrointestinal bleeding, and organ failure. There are no specific antidotes, but deferoxamine (an iron chelator) can be used if severe iron poisoning is suspected. Chronic overdose (from repeated excess dosing) leads to iron overload as above. Always adhere to recommended dosing regimens and lab monitoring to avoid this.\u003c\/p\u003e\n\u003ch2\u003eHow Supplied and Storage:\u003c\/h2\u003e\n\u003cp\u003eIMS iron sucrose injection comes in single-dose vials (2.5 mL, 5 mL, 10 mL), each containing the specified mg of iron at 20 mg\/mL. Store at room temperature (68–77°F, protect from freezing). Use sterile technique. After withdrawing a dose, administer promptly or refrigerate if needed (the label notes stability for several days if refrigerated, but practice is to use immediately). Discard any unused portion from the vial.\u003c\/p\u003e\n\u003ch2\u003ePatient Counseling:\u003c\/h2\u003e\n\u003cp\u003ePatients should be told this medication is for IV use only. They should expect the infusion to be given slowly, and to let staff know if they feel itchy, short of breath, dizzy, or have pain during the infusion. Advise them to report fever, muscle or joint pain, or any unusual symptoms afterwards. Emphasize importance of follow-up blood tests (hemoglobin, ferritin) to gauge response. Remind them not to take oral iron supplements (like ferrous sulfate) shortly before or after IV dosing unless instructed, since iron sucrose quickly replenishes stores. For nursing mothers, reassure that occasional IV iron exposure has not been shown to harm infants. Also counsel that stopping iron sucrose and seeking medical care is needed if symptoms worsen or if anemia symptoms (fatigue, pallor, dizziness) do not improve after treatment, since treatment of underlying cause may be needed.\u003c\/p\u003e\n\u003cp\u003eIron sucrose injection 20 mg\/mL (IMS) is an FDA-approved IV iron therapy for iron-deficiency anemia in CKD patients. It provides a reliable way to replenish iron stores when oral iron is insufficient or cannot be used. Proper use requires slow IV administration, monitoring for hypersensitivity, and periodic lab checks to avoid overload. When used as directed, it effectively improves anemia with generally good tolerance.\u003c\/p\u003e","brand":"International Medication Systems","offers":[{"title":"Default Title","offer_id":53791121113456,"sku":"76329-9200-01","price":259.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Iron-Sucrose-Injection-20-mg2_5-grams--International-Medication-Systems.jpg?v=1779195729"},{"product_id":"iron-sucrose-injection-20-mg-ml-single-dose-vial-5-ml-x-10-pack-rx","title":"Iron Sucrose Injection 20 mg\/mL SIngle-Dose Vial 10 mL x 5\/Pack (RX)","description":"\u003ch1\u003eIron Sucrose Injection (20 mg\/mL, 5 mL single-dose vial)\u003c\/h1\u003e\n\u003cp\u003eIron sucrose injection is an \u003cstrong\u003eintravenous iron replacement\u003c\/strong\u003e medication. Each single-use vial contains 100 mg elemental iron in 5 mL of solution (20 mg\/mL), provided as a sterile, brown aqueous solution of iron(III)-hydroxide in sucrose. The product is preservative-free (“contains no preservatives”) and must be used under medical supervision. The 5 mL vial delivers 100 mg of elemental iron; smaller (2.5 mL, 50 mg) and larger (10 mL, 200 mg) vials are also available. Iron sucrose is a prescription drug (e.g. Venofer® and generics) used primarily when oral iron cannot meet needs.\u003c\/p\u003e\n\u003ch2\u003eIndications\u003c\/h2\u003e\n\u003cp\u003eIron sucrose injection is approved for \u003cstrong\u003etreatment of iron‐deficiency anemia (IDA) in patients with chronic kidney disease (CKD)\u003c\/strong\u003e. This includes adults and children (≥2 years) on dialysis (hemodialysis or peritoneal) or not yet on dialysis. In CKD, patients often have ongoing iron losses and need rapid iron repletion, especially when on erythropoiesis‐stimulating agents (ESAs).\u003c\/p\u003e\n\u003cp\u003eAlthough not on FDA label, iron sucrose is frequently used off‐label for other severe IDA situations. For example, it may be given to patients with GI malabsorption (e.g. inflammatory bowel disease, celiac sprue, bariatric surgery), heavy menstrual bleeding, postpartum anemia, or chemotherapy‐induced anemia – essentially any case where oral iron is ineffective or not tolerated and rapid repletion is needed. In practice, clinical guidelines recommend considering IV iron for IDA if oral supplements fail or when correction is urgent. (Note: IV iron should not replace evaluation of underlying causes of anemia.)\u003c\/p\u003e\n\u003ch2\u003eHow It Works\u003c\/h2\u003e\n\u003cp\u003eThe iron in this product is bound in a sucrose complex. When infused IV, the complex dissociates: free iron (Fe³⁺) binds to plasma transferrin and is transported to bone marrow and other tissues. There, iron is incorporated into hemoglobin of developing red cells. Any excess iron is stored (mainly in liver, spleen, marrow) for later use. Because iron sucrose bypasses the gut, it rapidly raises serum iron and allows immediate availability for erythropoiesis. It is especially useful when gastrointestinal absorption is inadequate.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacokinetics:\u003c\/strong\u003e After infusion, serum iron and transferrin saturation (TSAT) rise quickly. (TSAT values remain elevated for about 24–48 hours, so levels should not be measured sooner than 2 days post-infusion.) Iron is gradually utilized or stored; the half-life is on the order of hours. The sucrose carrier is filtered by the kidneys (approximately 75% in 24 hours) and excreted.\u003c\/p\u003e\n\u003ch2\u003eDosage and Administration\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003ePreparation:\u003c\/strong\u003e Vials are for single use only (no preservatives), and any unused portion must be discarded. Inspect each vial before use; do not use if it is discolored or contains particulates. For infusion, iron sucrose may be used undiluted (IV push) or diluted in 0.9% sodium chloride. If diluting, use only saline and ensure a final concentration of 1–2 mg iron\/mL (i.e. dilute 100 mg in ≥50 mL saline). Do not mix with dextrose solutions, other drugs, or blood products in the same IV line.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdministration:\u003c\/strong\u003e Iron sucrose must be given \u003cstrong\u003eintravenously\u003c\/strong\u003e only – never intramuscularly or orally. It should be administered slowly to reduce adverse reactions. For example, a 100 mg dose can be given by a 2–5 minute IV push or a 15-minute infusion (diluted in ≤100 mL saline). Larger doses (200–400 mg) are typically given as infusions: e.g. 200 mg over ~15 minutes, 300 mg over ~1.5 hours, 400 mg over ~2–2.5 hours. Blood pressure should be monitored, and staff should observe the patient during and for ≥30 minutes after each dose (since iron sucrose can cause hypotension and allergic reactions). Emergency medications (e.g. epinephrine) must be readily available.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTypical Regimens (Adults):\u003c\/strong\u003e The total iron needed depends on the hemoglobin\/iron deficit. In CKD, a common target is ~1000 mg total. For example:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eHemodialysis (CKD-HD):\u003c\/strong\u003e 100 mg IV per dialysis session (2–3 times\/week) until total ~1000 mg. Each 100 mg is given as a slow push or short infusion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNon-dialysis CKD (CKD-ND):\u003c\/strong\u003e 200 mg IV weekly for 5 doses (total 1000 mg) or 500 mg twice (2 weeks apart). A 200 mg dose can be infused over ~15 minutes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePeritoneal dialysis (CKD-PD):\u003c\/strong\u003e 300 mg IV on day 1 and day 5 or 15, then 400 mg on day 29 (total 1000 mg). The 300–400 mg doses are infused over longer times (1.5–2.5 hours).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMaintenance:\u003c\/strong\u003e After initial correction, ongoing low-dose iron (e.g. 100 mg monthly or as needed) may be given to maintain stores. Iron sucrose treatment can be repeated if iron deficiency recurs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePediatric Patients:\u003c\/strong\u003e Iron sucrose is \u003cstrong\u003enot studied for initial correction\u003c\/strong\u003e in young children. For pediatric CKD patients on ESAs (≥2 years old), maintenance dosing was 0.5–2 mg\/kg IV (max 100 mg) every 2–4 weeks, which maintained hemoglobin in the target range in clinical studies. (In those studies, ~50% of children on 0.5–2 mg\/kg maintained hemoglobin 10.5–14 g\/dL on EPO.) Iron sucrose has \u003cstrong\u003enot\u003c\/strong\u003e been studied in infants or children under 2 years. Use in very young children requires extreme caution (cases of intestinal injury have been reported). Children on peritoneal dialysis may follow similar regimens with appropriate dilution and monitoring.\u003c\/p\u003e\n\u003ch2\u003eContraindications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAllergy:\u003c\/strong\u003e Do \u003cem\u003enot\u003c\/em\u003e give to anyone with a known hypersensitivity to iron sucrose or its components. Reactions to other parenteral iron products may also indicate risk.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIron overload:\u003c\/strong\u003e Do not administer if there is evidence of iron overload (e.g. hemochromatosis) or high iron stores (transferrin saturation \u0026gt;50%, ferritin \u0026gt;500–800 ng\/mL), as excess iron can deposit in organs. Patients should have documented iron deficiency before treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eWarnings and Precautions\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypersensitivity:\u003c\/strong\u003e Severe allergic or anaphylactic reactions can occur (though less frequently than with older iron dextrans). Monitor closely during and for 30+ minutes after infusion. Treat any signs of anaphylaxis immediately. Only administer when staff and resuscitation equipments are available. Patients with asthma or history of allergies may be at higher risk.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypotension:\u003c\/strong\u003e Rapid infusion can cause significant hypotension. Infuse slowly and monitor blood pressure. If hypotension or syncope occurs, stop infusion and take supportive measures (IV fluids, Trendelenburg position). In pregnancy, severe maternal hypotension could compromise the fetus.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIron overload:\u003c\/strong\u003e Because iron is not easily excreted, repeated large doses can lead to hemosiderosis. Regularly monitor hemoglobin, ferritin, and TSAT. Do not give further iron if ferritin\/TSAT indicate overload.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInfection:\u003c\/strong\u003e Iron can promote bacterial growth. Use with caution in patients with active infection. Some experts avoid IV iron in sepsis until infection is controlled.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdministration issues:\u003c\/strong\u003e Use only the recommended diluents and IV rates. Avoid mixing in the same IV line with incompatible drugs. (IV iron has no significant drug–drug interactions with oral agents since it bypasses the gut, but it should not be co-infused with incompatible IV medications.)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePost-injection observation:\u003c\/strong\u003e Patients should report any unusual symptoms (chest pain, difficulty breathing, severe headache, rash) during or shortly after the infusion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eSide Effects (Adverse Reactions)\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCommon (≥2%):\u003c\/strong\u003e Gastrointestinal upset (nausea, vomiting, diarrhea, constipation), headache, dizziness, muscle cramps, arthralgia, hypotension (usually mild\/transient), hypertension, flushing, itching or rash, injection-site pain or discoloration, and fatigue. These symptoms are usually mild.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSerious:\u003c\/strong\u003e Rare cases of severe anaphylaxis or anaphylactoid reactions (shocks, convulsions) have been reported. Other rare events include chest pain, rapid heart rate, respiratory distress, thrombosis (of vascular access in dialysis), and electrolyte disturbances. Case reports exist of seizures or hematologic reactions in severe iron overload, but these are extremely uncommon.\u003c\/p\u003e\n\u003cp\u003eAny severe reaction (e.g. difficulty breathing, swelling, intense rash, severe hypotension) warrants immediate discontinuation and emergency care. All adverse events should be reported to the prescribing physician and FDA MedWatch.\u003c\/p\u003e\n\u003ch2\u003eSpecial Populations\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePregnancy:\u003c\/strong\u003e Category B. Studies where iron sucrose was given after the first trimester showed no increased risk of fetal abnormalities. First-trimester use has not been well studied. It is well recognized that untreated maternal IDA can cause poor outcomes (prematurity, low birth weight, postpartum complications), so correcting iron deficiency in pregnancy is important. If IV iron is needed (e.g. severe anemia, oral intolerance), it can be given after the first trimester with caution. Monitor both mother and fetus during infusion for any adverse signs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLactation:\u003c\/strong\u003e Iron sucrose is excreted in breast milk, but studies of 100–300 mg IV doses have \u003cstrong\u003enot reported any adverse effects in breastfed infants\u003c\/strong\u003e. No impact on milk production has been observed. Given the benefits of treating maternal anemia and the lack of reported harm to infants, IV iron sucrose is generally considered safe during breastfeeding. However, mothers should discuss risks\/benefits with their doctor.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePediatric:\u003c\/strong\u003e As above, use is limited. Not approved for infants \u0026lt;2 years. Use only if clearly indicated and with pediatric expertise; infants and toddlers are more vulnerable to iron toxicity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeriatric:\u003c\/strong\u003e Clinical studies included many older adults with no unusual toxicity, so dosing does not need adjustment based on age alone. However, older patients may have comorbidities (heart disease, kidney insufficiency) that necessitate slower administration and careful monitoring.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eMonitoring\u003c\/h2\u003e\n\u003cp\u003eBefore and during therapy, monitor hemoglobin\/hematocrit, serum ferritin, and transferrin saturation (TSAT) to gauge response. Because IV iron acutely raises TSAT and serum iron, measure these at least 24–48 hours \u003cem\u003eafter\u003c\/em\u003e infusion. Do not re-dose iron if ferritin exceeds ~500–800 ng\/mL or TSAT \u0026gt;50%, to avoid overload. Regularly check for signs of anaphylaxis (especially on the first dose). Vital signs should be checked during and after each infusion.\u003c\/p\u003e\n\u003ch2\u003eStorage and Handling\u003c\/h2\u003e\n\u003cp\u003eStore the vials at controlled room temperature, 20–25 °C (68–77 °F); brief excursions to 15–30 °C are allowed. Protect from freezing and heat. Keep in the original carton to protect from light. After drawing a dose, administer promptly or store the syringe (prepared solution) refrigerated; used vials or syringes must be discarded if not used immediately.\u003c\/p\u003e\n\u003cp\u003eIron sucrose injection (20 mg\/mL, 5 mL vial) is an FDA-approved IV iron therapy for iron-deficiency anemia in CKD patients. It provides elemental iron (100 mg per vial) via a sucrose‐iron complex. When filled, it must be given intravenously under slow infusion with appropriate monitoring. It is typically used in hemodialysis and non-dialysis CKD (often 100–200 mg doses), and is also used off-label for other refractory IDA cases. Its common side effects include gastrointestinal upset and mild hypotension; rare but serious effects include hypersensitivity and iron overload. In pregnancy and lactation it is considered relatively safe, whereas infants require caution. Overall, with proper dosing and monitoring, iron sucrose is a generally well-tolerated and effective method to replenish iron stores when oral therapy is insufficient.\u003c\/p\u003e","brand":"International Medication Systems","offers":[{"title":"Default Title","offer_id":53791234851184,"sku":"76329-9201-01","price":625.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Iron-Sucrose-Injection-20-mg-5-ml--international-Medication-Systems-76329-9201-01.jpg?v=1779203595"},{"product_id":"iron-sucrose-injection-100-mg-elemental-iron-per-5-ml-single-dose-5-ml-x-10-pack-rx","title":"Iron Sucrose Injection 100 mg Elemental Iron per 5 mL Single-Dose 5 mL x 10\/Pack (RX)","description":"\u003ch1\u003e\u003cbr\u003e\u003c\/h1\u003e\n\u003ch1\u003eIron Sucrose Injection (100 mg\/5 mL, Sandoz)\u003c\/h1\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eIron sucrose injection (20 mg\/mL, 5 mL vial, i.e. 100 mg elemental iron per vial) is a prescription \u003cstrong\u003eintravenous iron\u003c\/strong\u003e solution. It is provided by Sandoz (manufactured by Rafarm) in cartons of 10 single-use vials. Each 5 mL vial contains 100 mg of elemental iron as a polynuclear iron(III)–hydroxide complex with sucrose (iron sucrose). The solution is formulated with approximately 30% sucrose and sodium chloride (for tonicity), and is adjusted with sodium hydroxide to pH ~10.5–11. Inactive ingredients are just water and sodium hydroxide. There are no preservatives, so vials are single-use only.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eIndications:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eBy FDA approval, iron sucrose injection is indicated for iron-deficiency anemia in patients with chronic kidney disease (CKD). This includes adults and children (≥2 years old) on hemodialysis, peritoneal dialysis, or non-dialysis CKD who need iron repletion. In these patients, iron is often combined with erythropoiesis-stimulating agents. (Because of its rapid iron delivery, it is much more potent than oral iron in these settings.) In practice, clinicians also use IV iron sucrose off-label for severe IDA from other causes – for example, in pregnancy\/post-partum anemia, inflammatory bowel disease, heavy uterine bleeding, or chemotherapy – whenever oral iron fails or is not tolerated. Professional guidelines generally endorse IV iron when oral therapy is inadequate or too slow, since untreated IDA (especially during pregnancy) carries risks like preterm birth, low birthweight, and severe maternal anemia.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eHow It Works:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eAfter IV administration, the iron–sucrose complex dissociates, releasing iron. Free iron binds to blood transferrin and is carried to target cells (especially erythroid precursors in bone marrow). There, iron is incorporated into hemoglobin as red blood cells form. Excess iron is stored in the liver, spleen, and bone marrow for later use. Because the iron bypasses the gut, serum iron and transferrin saturation rise quickly after infusion; typical assays should be measured ≥2 days post-dose to reflect steady status. The sucrose carrier is primarily cleared renally. In healthy adults, the iron clearance half-life is about 6 hours.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eDosage and Administration:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eIron sucrose must be given \u003cstrong\u003eintravenously\u003c\/strong\u003e (IV) only – never by mouth or IM. It can be administered as a slow IV push (undiluted) or as an infusion (diluted in saline). Use only 0.9% sodium chloride for dilution and do not mix with other medications or dextrose solutions. The final iron concentration should be ≥1 mg\/mL if diluted. Prior to infusion, inspect vials for particulates or discoloration and do not use if abnormal.\u003c\/p\u003e\n\u003ch3\u003eDosing varies by patient:\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eHemodialysis-dependent CKD (HDD-CKD):\u003c\/strong\u003e Often 100 mg IV per dialysis session (2–3 times weekly) until ~1,000 mg total iron is given. (Each 100 mg dose can be a 2–5 minute IV push or a ~15-minute infusion.).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNon-dialysis CKD (NDD-CKD):\u003c\/strong\u003e A common regimen is 200 mg IV weekly for 5 weeks (total 1,000 mg). Alternatively, 500 mg infusions twice (two weeks apart) have been used.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePeritoneal dialysis CKD (PDD-CKD):\u003c\/strong\u003e Typical course: 300 mg IV, then 300 mg two weeks later, then 400 mg two weeks after that (total 1,000 mg over ~4 weeks).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePediatric (≥2 years):\u003c\/strong\u003e For iron maintenance in dialysis patients on ESAs, studies used 0.5–2 mg\/kg IV (max 100 mg) every 2–4 weeks. This dosing maintained target hemoglobin in children. Dosing above 100 mg is rare in children. Iron sucrose has \u003cem\u003enot\u003c\/em\u003e been studied or approved for initial iron repletion in pediatric patients (\u0026lt;2 years), so use in infants and toddlers is usually avoided.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor all patients, each vial is single-use only. After withdrawing a dose, administer it promptly. Store vials in original carton at controlled room temperature (68–77 °F or 20–25 °C); excursions 59–86 °F (15–30 °C) are allowed. Do \u003cstrong\u003enot freeze\u003c\/strong\u003e. Discard any unused portion immediately after a single use.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eSide Effects:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eCommon adverse effects (≥2%) in adults include gastrointestinal symptoms (nausea, vomiting, diarrhea), headache, dizziness, hypotension (usually mild\/transient), itching or rash (pruritus), injection-site reactions (pain, discoloration), myalgia or muscle cramps, back pain, arthralgia, and chest or extremity pain. These usually occur during or shortly after infusion. In clinical trials, reported adult adverse reactions included diarrhea, headache, dizziness, joint and back pain, cramps, and hypertension or edema.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eSerious adverse reactions are rare but important. The most critical is \u003cstrong\u003ehypersensitivity\/anaphylaxis\u003c\/strong\u003e. Severe allergic reactions (rash, pruritus, bronchospasm, angioedema, hypotension, shock) have occurred with IV iron, though incidence is low. Hypotension is also noted as a risk if infusion is too rapid or patient is sensitive. Other serious effects (rare) can include seizures, breathing difficulty, or severe cardiac events. If any sign of anaphylaxis occurs, stop infusion immediately and administer appropriate emergency care (epinephrine, IV fluids, etc.) \u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eWarnings and Precautions:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eIron sucrose injection carries several key warnings. \u003cstrong\u003eHypersensitivity:\u003c\/strong\u003e All doses should be given in a setting where resuscitation equipment and trained personnel are available. Observe the patient during infusion and for ≥30 minutes afterward for any allergic symptoms. \u003cstrong\u003eHypotension:\u003c\/strong\u003e Infuse slowly. Monitor blood pressure continuously (especially for large or rapid doses); treat any significant hypotension by slowing or stopping the infusion and providing IV fluids or other support. \u003cstrong\u003eIron overload:\u003c\/strong\u003e Because iron is not easily excreted, repeated dosing can cause iron accumulation (hemosiderosis). Periodically monitor hemoglobin, ferritin, and transferrin saturation (TSAT) during therapy. Do not give further iron if ferritin is very high or TSAT \u0026gt;50%. \u003cstrong\u003eInfections:\u003c\/strong\u003e Use caution in patients with active infection; iron can promote bacterial growth. In sepsis or active infections, IV iron is usually avoided until infection is controlled.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eContraindications:\u003c\/strong\u003e Do not use in patients with known sensitivity to iron sucrose or any component. Also avoid in patients with acute iron overload or conditions like hemochromatosis where iron is already excess.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePregnancy:\u003c\/strong\u003e Iron sucrose is classified as Pregnancy Category B. Untreated maternal IDA is a serious risk factor for both mother and baby (e.g. anemia, preterm delivery, low birth weight), so treatment of significant IDA in pregnancy is important. Published data show no increased birth defects in women who received IV iron sucrose \u003cem\u003eafter\u003c\/em\u003e the first trimester. First-trimester data are limited, so IV iron is generally reserved for use in the 2nd or 3rd trimester, or in urgent situations. Even so, any maternal hypotension or allergy during infusion could harm the fetus, so monitor mother (and fetus as needed) during administration.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eLactation:\u003c\/strong\u003e Iron sucrose is excreted in breast milk, but case reports (100–300 mg IV doses) have not found any adverse effects in breastfed infants. There were no reported impacts on milk production. Given the benefits of treating maternal anemia, IV iron can be used during breastfeeding if indicated. Mothers should discuss breastfeeding and any concerns with their doctor.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eAdministering and Monitoring:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eBecause it is intravenous, use proper IV technique. Do not mix iron sucrose with other IV drugs or solutions. Do not dilute to \u0026lt;1 mg\/mL. Continuous monitoring of vital signs during infusion is standard. Follow-up labs (CBC, ferritin, TSAT) should be checked to gauge response and avoid overload. In dialysis patients, hemoglobin goals (e.g. 10–11 g\/dL) guide the total iron course; once adequate iron repletion is achieved (often ferritin ~500–800 ng\/mL), stop further iron.\u003c\/span\u003e\u003cspan class=\"VODHU pdMy8\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePediatrics:\u003c\/strong\u003e The safety and effectiveness of iron sucrose have \u003cem\u003enot\u003c\/em\u003e been established in pediatric patients for initial iron repletion (especially under age 2). In children ≥2 years on dialysis with ESA therapy, maintenance dosing (0.5–2 mg\/kg IV) was studied and helped maintain target hemoglobin. Iron sucrose should be used in children only under close medical supervision and generally only for dialysis-related anemia or specific indications under pediatric guidance.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGeriatrics:\u003c\/strong\u003e Clinical studies included many older patients (≥65 years) and no age-specific adverse reactions were noted. Dose selection for elderly patients should take into account general organ function and co-morbidities, as with any patient.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eStorage:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eStore vials in original carton at room temperature (68–77° F, excursions 59–86° F). Do not freeze. Protect from excessive heat. After mixing or withdrawing, use promptly (the manufacturer notes diluted solutions are stable 7 days refrigerated, but common practice is immediate use). Discard any vial or syringe that has been opened and not fully use.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eSandoz Iron Sucrose (100 mg\/5 mL) is a sterile IV iron preparation for treating iron-deficiency in CKD-related anemia. By delivering iron directly into blood, it rapidly replenishes iron stores for hemoglobin synthesis. It requires careful administration: slow IV infusion, monitoring for allergic reactions and blood pressure, and lab checks to avoid overload. Side effects are usually mild (GI upset, headache, injection-site discomfort, hypotension), but rare severe hypersensitivity can occur. When used as directed in the right patients, it is an effective option to restore iron in those who cannot use or do not respond to oral iron.\u003c\/span\u003e\u003c\/p\u003e","brand":"Sandoz","offers":[{"title":"Default Title","offer_id":53791299404144,"sku":"00781-3485-95","price":279.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Iron-Sucrose-Injection-100-mg-Elemental-Iron-per-5-mL-Single-Dose.jpg?v=1779205815"},{"product_id":"ferrlecit-sodium-ferric-gluconate-complex-sucrose-injection-62-5-mg-elemental-iron-5-ml-x-10-box","title":"Ferrlecit Sodium Ferric Gluconate Sucrose Injection 62.5 mg Elemental Iron 5 mL x 10\/Box (RX)","description":"\u003ch1\u003eFerrlecit (Sodium Ferric Gluconate Complex in Sucrose) Injection, 62.5 mg\/5 mL\u003c\/h1\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eFerrlecit is an intravenous iron‐replacement preparation (brand of sodium ferric gluconate complex). It is a colloidal carbohydrate‐stabilized iron solution; each 5 mL single‐dose vial delivers \u003cstrong\u003e62.5 mg elemental iron (12.5 mg\/mL)\u003c\/strong\u003e. In this formulation, ferric iron (Fe³⁺) is bound as a sodium ferric gluconate complex in a 20% sucrose solution (pH ~7.7–9.7). The solution has a characteristic deep red color due to ferric oxide linkages. Chemically, Ferrlecit is a high‐molecular‐weight (~300–440 kDa) iron‐gluconate complex. It provides a controlled release of iron to the body and contains benzyl alcohol (as a preservative), which precludes use in neonates. As an iron preparation, Ferrlecit’s purpose is to \u003cstrong\u003ereplete total-body iron stores\u003c\/strong\u003e when oral iron is inadequate.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eMechanism of Action:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eThe ferric iron in Ferrlecit is taken up by the reticuloendothelial system and slowly released to bind transferrin. Once bound to transferrin, the iron is delivered to the bone marrow for hemoglobin synthesis and to other tissues (including myoglobin and iron‐dependent enzymes). Iron is critical for hemoglobin to carry oxygen and for enzymatic reactions (e.g. ribonucleotide reductase for DNA synthesis). Administering Ferrlecit replenishes iron needed for red blood cell production in iron‐deficient patients. The carbohydrate (gluconate) and sucrose stabilize the ferric iron in solution, minimizing free “unbound” iron and reducing oxidative toxicity.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eClinical Uses:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eFerrlecit is FDA-approved for iron deficiency anemia in chronic kidney disease (CKD) patients on hemodialysis who are receiving erythropoiesis-stimulating agents. It is indicated for adults and for pediatric patients ≥6 years old with CKD on dialysis. By providing intravenous iron, Ferrlecit helps achieve adequate hemoglobin levels in patients who lose iron in dialysis and who do not absorb sufficient iron orally. In practice, it is often used when oral iron fails or cannot be tolerated. (Note: In adults without CKD, other IV iron products may be preferred; Ferrlecit’s labeled use is specific to dialysis patients on epoetin therapy.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eDosage and Administration:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eFerrlecit is administered \u003cstrong\u003eintravenously by slow injection or infusion\u003c\/strong\u003e under medical supervision. Important dosing and preparation points include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDose and Concentration:\u003c\/strong\u003e Each vial contains 62.5 mg elemental iron in 5 mL (12.5 mg\/mL). Because the usual adult dose is 125 mg, two vials (10 mL) are typically used per dialysis session.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdult dosing:\u003c\/strong\u003e The recommended adult dose for repletion is usually \u003cstrong\u003e125 mg elemental iron per session\u003c\/strong\u003e (often given as 10 mL). This can be administered either as:\n\u003cul\u003e\n\u003cli\u003e\n\u003cem\u003eIntravenous infusion:\u003c\/em\u003e 125 mg diluted in 100 mL of normal saline (0.9% NaCl) infused over ~60 minutes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cem\u003eSlow IV push:\u003c\/em\u003e 125 mg undiluted (in 10 mL) given slowly (no faster than 12.5 mg\/min).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePediatric dosing (≥6 years):\u003c\/strong\u003e Typically 1.5 mg\/kg (0.12 mL\/kg) elemental iron per session, diluted in 25 mL saline over 1 hour.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdministration precautions:\u003c\/strong\u003e Ferrlecit vials are \u003cem\u003esingle-dose\u003c\/em\u003e and contain benzyl alcohol preservative. Do \u003cstrong\u003enot\u003c\/strong\u003e mix Ferrlecit with any other drugs or IV solutions (including dextrose, calcium solutions, or parenteral nutrition). The only compatible diluent is 0.9% sodium chloride. Inspect the solution before use; it should be a clear, dark brown liquid without particulate. If diluted, use the solution immediately.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInfusion setup:\u003c\/strong\u003e Use dedicated IV line with normal saline; flush line before and after administration to avoid venous irritation. Do not administer Ferrlecit by any route other than intravenous.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTotal treatment course:\u003c\/strong\u003e Iron repletion often requires multiple doses. Clinically, a full replacement course may total ~1000 mg of elemental iron (e.g. 8 doses of 125 mg) administered over several dialysis sessions. Doses above 125 mg\/session are not recommended due to increased risk of reactions. Repeat treatment only if iron deficiency recurs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eAdverse Reactions (Side Effects):\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eCommon reactions include \u003cstrong\u003egastrointestinal effects\u003c\/strong\u003e and injection-related symptoms. In clinical studies, ≥10% of adults reported: nausea, vomiting, diarrhea, injection-site reaction (pain, swelling), hypotension, muscle cramps (leg cramps), hypertension, dizziness, dyspnea (shortness of breath), chest pain, and leg cramps. In children (6–15 years), the most frequent (≥10%) were hypotension, headache, hypertension, tachycardia, and vomiting. Generally, reactions are mild-to-moderate; gastrointestinal symptoms and injection-site discomfort were common.\u003c\/p\u003e\n\u003ch2\u003eSerious Reactions and Precautions:\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypersensitivity\/Anaphylaxis:\u003c\/strong\u003e Although rare, \u003cstrong\u003eanaphylactic-type allergic reactions\u003c\/strong\u003e can occur (some life-threatening or fatal). These may manifest as chest pain, lightheadedness, rash, bronchospasm, or shock. \u003cstrong\u003eMonitoring\u003c\/strong\u003e: Patients must be monitored during and for at least 30 minutes after each dose. Treat immediately if an allergic reaction occurs (epinephrine, IV steroids, and supportive care at the ready). Do \u003cstrong\u003enot\u003c\/strong\u003e administer Ferrlecit if severe allergy to iron–carbohydrate complexes is known.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypotension:\u003c\/strong\u003e Acute drops in blood pressure can happen during or shortly after infusion. Monitor blood pressure and symptoms throughout infusion. If hypotension occurs, slow or stop the infusion until stabilized.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIron Overload:\u003c\/strong\u003e Avoid administering Ferrlecit when iron stores are already high. Regularly check hematologic indices (hemoglobin, ferritin, transferrin saturation). \u003cstrong\u003eContraindication\u003c\/strong\u003e: Do not give Ferrlecit to patients with existing iron overload. Overload may exacerbate organ damage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBenzyl Alcohol Toxicity:\u003c\/strong\u003e Ferrlecit contains benzyl alcohol (preservative). Premature or low-birth-weight infants are at risk of “gasping syndrome” if exposed to benzyl alcohol . Thus, Ferrlecit should not be used in neonates or infants, and caution is advised in pregnant patients.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePregnancy\/Lactation:\u003c\/strong\u003e Use in pregnancy only if clearly needed (“high risk” category). Hypersensitivity reactions can affect the fetus; benzyl alcohol is hazardous to the fetus. Breastfeeding is not recommended during treatment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOther Contraindications:\u003c\/strong\u003e Do not use in patients with known hypersensitivity to sodium ferric gluconate or any inactive ingredients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCommon Side Effects Summary:\u003c\/strong\u003e These may include nausea, vomiting, diarrhea, headache, muscle cramps, dizziness, rash, pruritus, hypertension or hypotension, cough, and injection-site reactions. Most resolve within hours and are managed supportively. If severe symptoms arise, discontinue the dose and provide appropriate care.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Points for Practitioners:\u003c\/strong\u003e Ferrlecit is a targeted IV iron therapy for dialysis patients. It should always be administered slowly with resuscitation measures available. Monitor patients’ vital signs and iron indices. Ensure the correct dose (62.5 mg\/vial) and follow dilution guidelines (normal saline only). Always inform patients about possible allergic reactions and instruct them to report any unusual symptoms immediately.\u003c\/p\u003e","brand":"Sanofi Aventis","offers":[{"title":"Default Title","offer_id":53791349178736,"sku":"00024-2792-10","price":499.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Ferrlecit-Sodium-Ferric-Gluconate-Complex-Sucrose-Injection.jpg?v=1779209820"},{"product_id":"injectafer-ferric-carboxymaltose-100-mg-iron-replacement-injection-2-ml-rx","title":"Injectafer Ferric Carboxymaltose 100 mg IV Iron Infusion Injection 2 mL (RX)","description":"\u003ch1\u003eInjectafer (Ferric Carboxymaltose) 100 mg – Intravenous Iron Infusion Injection\u003c\/h1\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003e\u003cstrong\u003eInjectafer\u003c\/strong\u003e (generic \u003cem\u003eferric carboxymaltose\u003c\/em\u003e) is a parenteral iron preparation used to treat iron-deficiency anemia (IDA) when oral iron is not tolerated or effective. It is a stable colloidal complex of trivalent iron (Fe³⁺) bound to a carboxymaltose carbohydrate shell. Each mL of Injectafer contains 50 mg of elemental iron (so a 2 mL vial contains 100 mg iron). After IV administration, the complex is taken up by reticuloendothelial cells and slowly releases iron to transferrin for hemoglobin synthesis, with minimal free (labile) iron in the plasma. Injectafer is supplied as a sterile dark-brown solution (50 mg\/mL) in single-dose vials. Packaging includes 2 mL vials (100 mg iron) as well as larger 15 mL (750 mg) and 20 mL (1000 mg) vials\u003c\/span\u003e.\u003c\/p\u003e\n\u003ch2\u003eIndications and Use\u003c\/h2\u003e\n\u003cp\u003eInjectafer is indicated for treating iron deficiency anemia in patients who cannot take adequate oral iron. Specifically, it is approved for:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIDA in adults and children (≥1 year)\u003c\/strong\u003e with intolerance or inadequate response to oral iron.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIDA in adult patients with chronic kidney disease (CKD)\u003c\/strong\u003e who are not on dialysis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIron deficiency in heart failure (NYHA class II\/III)\u003c\/strong\u003e: Injectafer is FDA-approved to improve exercise capacity in iron-deficient adults with symptomatic chronic heart failure. (European and American guidelines recommend IV ferric carboxymaltose in such HF patients to improve symptoms and quality of life.)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBeyond these label indications, intravenous ferric carboxymaltose is often used in other settings of significant iron deficiency (e.g. heavy menstrual bleeding, postpartum anemia, inflammatory bowel disease, or preoperative anemia) when rapid repletion is needed or oral therapy fails.\u003c\/p\u003e\n\u003ch2\u003eDosage and Administration\u003c\/h2\u003e\n\u003cp\u003eDosage depends on body weight and iron deficit. For \u003cstrong\u003eadults ≥50 kg\u003c\/strong\u003e, the recommended total dose per treatment course is 1,500 mg, given as two 750 mg IV doses at least 7 days apart. An alternative regimen is a single dose of 15 mg\/kg (up to 1,000 mg). For \u003cstrong\u003epatients \u0026lt;50 kg\u003c\/strong\u003e, give 15 mg\/kg IV in two doses separated by ≥7 days. (Heart-failure patients follow a specific weight-based schedule per product labeling.) If anemia or iron deficiency persists, courses may be repeated after re-evaluation.\u003c\/p\u003e\n\u003cp\u003eInjectafer must be administered \u003cstrong\u003eintravenously\u003c\/strong\u003e. The label advises either a slow IV push or a diluted infusion. For infusion, up to 1,000 mg iron may be diluted in ≤250 mL of 0.9% saline (maintaining ≥2 mg\/mL) and infused over at least 15 minutes. For a direct IV push, the injection should be given very slowly – roughly 100 mg (2 mL) per minute (e.g. a 750 mg dose over ~7–8 minutes). In practice, 750 mg is often administered as an infusion over ≥15 minutes. During and after administration, vital signs should be monitored. Patients must be observed for at least 30 minutes post-dose for signs of adverse reaction. \u003cstrong\u003eAvoid extravasation:\u003c\/strong\u003e if the drug leaks out of the vein, it can cause long-lasting brown skin discoloration; stop the injection if this occurs.\u003c\/p\u003e\n\u003ch2\u003eSide Effects and Precautions\u003c\/h2\u003e\n\u003cp\u003eCommon side effects (≥2% incidence) include \u003cstrong\u003enausea, flushing, dizziness, injection-site reactions, rash\/erythema, and hypertension\u003c\/strong\u003e. Headache, vomiting and other GI symptoms have also been reported. Because Injectafer contains iron, stools may darken temporarily. Patients should be warned about these expected effects.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAllergic reactions:\u003c\/strong\u003e Serious hypersensitivity (including anaphylaxis) can occur. In clinical trials, life-threatening reactions were very rare (~0.1%), but because of the potential severity, administer Injectafer only where resuscitation measures are available. Monitor patients for signs of allergic reaction (rash, difficulty breathing, hypotension, etc.) during and for 30 minutes after the infusion. If a severe reaction occurs, stop the infusion immediately. Patients with a history of sensitivity to any IV iron (especially dextran or carboxymaltose) should not receive Injectafer.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHypophosphatemia:\u003c\/strong\u003e A distinctive adverse effect of ferric carboxymaltose is \u003cstrong\u003elow blood phosphate\u003c\/strong\u003e. Injectafer can provoke transient hypophosphatemia – occasionally severe (leading to osteomalacia or fractures) – especially after repeated dosing. Most cases resolve within ~3 months. Risk factors include malnutrition, vitamin D deficiency, certain GI disorders, or medications affecting phosphate handling. The label advises correcting any pre-existing low phosphate and monitoring phosphate in at-risk patients during repeat courses. Patients should be educated to report muscle weakness or bone pain, which could indicate significant hypophosphatemia.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOther:\u003c\/strong\u003e Transient blood pressure changes (mostly hypertension) and flushing are common during or shortly after the infusion. Monitor blood pressure and treat as needed. IV iron can also cause changes in liver enzymes or iron indices; routine lab monitoring (CBC, iron studies) should be done before and periodically during therapy. Injectafer is contraindicated in patients with known allergy to ferric carboxymaltose or any of its components. Like all IV iron, it should be used cautiously in active infections.\u003c\/p\u003e\n\u003cp\u003eInjectafer is \u003cstrong\u003efor IV use only\u003c\/strong\u003e. It is pregnancy category C (safety in pregnancy is not fully established); severe maternal reactions could potentially affect the fetus. Decisions in pregnancy must weigh maternal benefit versus fetal risk. Nursing mothers may transfer some iron to breast milk, but this is generally not a contraindication.\u003c\/p\u003e\n\u003ch2\u003eHow It Works\u003c\/h2\u003e\n\u003cp\u003eFerric carboxymaltose is a polynuclear iron(III)-hydroxide complex (~150 kDa) stabilized by a carbohydrate shell. After IV infusion, macrophages take up the complex and gradually break it down. The released iron binds to transferrin and is carried to the bone marrow for hemoglobin production. Because the complex is stable, there is little free (labile) iron released in plasma, reducing the risk of oxidative stress. This allows large doses of iron to be given more safely than older IV formulations. In essence, Injectafer serves as an iron reservoir that corrects the body’s iron deficit.\u003c\/p\u003e\n\u003ch2\u003eStorage and Handling\u003c\/h2\u003e\n\u003cp\u003eInjectafer vials are single-use. They should be stored at room temperature. Do not mix Injectafer with other medications or diluents besides 0.9% saline. Discard any unused solution (the label states \u003cstrong\u003e“Discard Unused Portion”\u003c\/strong\u003e). Inspect the vial before use; the solution is dark brown and should not be used if it is visibly discolored or cloudy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIn summary\u003c\/strong\u003e, Injectafer 100 mg\/2 mL (ferric carboxymaltose) is a high-dose IV iron indicated for IDA when oral iron is inadequate. It delivers 50 mg Fe³⁺ per mL in a stable complex. Proper dosing, slow IV administration, and monitoring are essential. Common side effects are mild, but clinicians must watch for rare serious reactions (allergy and hypophosphatemia). As with any medication, treatment should follow official guidelines and individual patient needs.\u003c\/p\u003e","brand":"American Regent","offers":[{"title":"Default Title","offer_id":53793217347952,"sku":"00517-0602-01","price":349.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Injectafer-Ferric-Carboxymaltose-100-mg-Iron-Replacement-Injection.jpg?v=1779279493"},{"product_id":"sodium-ferric-gluconate-complex-in-sucrose-injection-62-5mg","title":"Sodium Ferric Gluconate Complex in Sucrose Injection 62.5mg SDV 5mL 10\/Pack (RX)","description":"\u003ch1\u003eSodium Ferric Gluconate Complex in Sucrose Injection 62.5 mg\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003eOverview:\u003c\/strong\u003e Sodium ferric gluconate complex in sucrose injection is a prescription \u003cem\u003eintravenous iron supplement\u003c\/em\u003e formulated to rapidly replenish iron stores and boost hemoglobin and red blood cell production. This iron infusion contains \u003cstrong\u003e62.5 mg elemental iron per 5 mL single-dose vial\u003c\/strong\u003e (12.5 mg\/mL), in a stable ferric (Fe³⁺)–gluconate–sucrose complex. By delivering iron directly into the bloodstream, it overcomes the limitations of oral iron (poor absorption or gastrointestinal side effects) and is specifically FDA-indicated for \u003cstrong\u003eiron deficiency anemia in chronic kidney disease (CKD) patients on hemodialysis who are also receiving epoetin therapy\u003c\/strong\u003e. This medical-grade iron infusion is shipped as a pack of 10 vials (single-use each) for use under physician supervision. When administered correctly, it helps restore iron levels, improve hemoglobin (Hgb), and alleviate anemia symptoms (fatigue, weakness) by supporting healthy red blood cell production.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey features:\u003c\/strong\u003e Each 5 mL vial contains 62.5 mg of elemental iron as the sodium salt of ferric gluconate in 20% w\/v sucrose. Sodium ferric gluconate (generic) is the active ingredient (also marketed under the brand name \u003cem\u003eFerrlecit\u003c\/em\u003e in the US) and is provided in a clear, dark brown aqueous solution. This \u003cstrong\u003eintravenous iron therapy\u003c\/strong\u003e is administered either as a slow infusion or injection during dialysis. Because it contains \u003cstrong\u003ebenzyl alcohol\u003c\/strong\u003e (9 mg\/mL), it is not recommended for neonates. The solution is supplied in \u003cstrong\u003esingle-dose vials\u003c\/strong\u003e—use one vial per intravenous dose and discard any unused portion. Store at controlled room temperature (68–77°F) and protect from freezing. \u003cstrong\u003ePrescription Only:\u003c\/strong\u003e This product must be administered by qualified healthcare professionals in a clinical setting.\u003c\/p\u003e\n\u003ch2\u003eUses and Applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTreat Iron Deficiency Anemia:\u003c\/strong\u003e Specifically indicated for iron deficiency anemia in adult and pediatric patients (≥6 years) with chronic kidney disease on hemodialysis who are receiving supplemental epoetin (erythropoiesis-stimulating agent) therapy. It replenishes iron stores, allowing the body to produce hemoglobin and healthy red blood cells.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRapid Iron Repletion:\u003c\/strong\u003e Ideal for patients who cannot tolerate or absorb oral iron (e.g. gastrointestinal issues, inflammatory bowel disease, or CKD). By intravenous infusion, iron is delivered directly to the bloodstream, providing \u003cem\u003efast correction\u003c\/em\u003e of anemia and reducing fatigue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDialysis Center Use:\u003c\/strong\u003e Commonly used in hemodialysis clinics and hospitals. During dialysis sessions, the iron solution can be given in tandem with routine care to improve patient iron levels without extra clinic visits. It’s often prescribed when lab tests show low ferritin or transferrin saturation (TSAT) despite oral iron.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNutrient Infusion Therapy:\u003c\/strong\u003e As a blood-building nutrient injection, it helps support \u003cstrong\u003eoxygen transport\u003c\/strong\u003e throughout the body. Iron is critical for hemoglobin\/myoglobin synthesis to maintain oxygen delivery to tissues. This injection \u003cem\u003efortifies blood health\u003c\/em\u003e and energy levels in anemic patients, aligning with overall wellness goals for CKD-related anemia management.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeneric Name:\u003c\/strong\u003e Sodium Ferric Gluconate Complex in Sucrose (iron gluconate injection)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBrand Name:\u003c\/strong\u003e (e.g. Ferrlecit®) – generic product is bioequivalent.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eActive Ingredient:\u003c\/strong\u003e Ferric (Fe³⁺) gluconate with sucrose stabilizer.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrength:\u003c\/strong\u003e 62.5 mg elemental iron per 5 mL vial (12.5 mg\/mL).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Clear, dark brown sterile solution for intravenous injection. Each mL contains 9 mg benzyl alcohol (preservative). pH ~7.7–9.7.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePackaging:\u003c\/strong\u003e Box of 10 single-dose 5 mL vials (NDC may vary by manufacturer). Each vial is for one-time use only.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdministration Route:\u003c\/strong\u003e Intravenous infusion or slow IV push (i.e. \u003cem\u003evenous injection into bloodstream\u003c\/em\u003e).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Room temperature (68–77°F); do not freeze. Protect from light\/shocks. Use immediately after preparation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory:\u003c\/strong\u003e FDA-approved iron replacement therapy. Prescription drug only (requires licensed healthcare provider).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eHow to Use\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMedical Supervision:\u003c\/strong\u003e Administer this IV iron injection only in a clinical setting (hospital\/dialysis clinic) under the guidance of trained medical staff. Ensure resuscitation equipment is available for allergic reactions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePreparation:\u003c\/strong\u003e Inspect vial for particulate matter\/discoloration. Use only if solution is clear and vial intact. Withdraw the calculated dose using aseptic technique and dilute in 0.9% sodium chloride (normal saline) compatible with label instructions. \u003cem\u003eDo not mix with other medications or dextrose solutions; dilute only in normal saline.\u003c\/em\u003e Shake gently to mix, and \u003cstrong\u003euse immediately after dilution\u003c\/strong\u003e. Discard any unused portion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInfusion\/Injection:\u003c\/strong\u003e Connect IV line to patient’s access (e.g. venous line). Administer dose \u003cem\u003eslowly\u003c\/em\u003e as follows:\n\u003cul\u003e\n\u003cli\u003e\n\u003cem\u003eIV Infusion:\u003c\/em\u003e Dilute the vial(s) in 100 mL of 0.9% NaCl. Infuse over approximately \u003cstrong\u003e1 hour\u003c\/strong\u003e per hemodialysis session.\u003c\/li\u003e\n\u003cli\u003e\n\u003cem\u003eSlow IV Push:\u003c\/em\u003e If instructed, the undiluted 10 mL (125 mg) dose may be given via slow IV injection (not faster than 12.5 mg\/minute, i.e. ~8 minutes per 10 mL) at the end of dialysis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMonitoring:\u003c\/strong\u003e Check patient’s blood pressure and status during and after administration. Observe for signs of allergy or hypotension as noted below. Adjust infusion rate if necessary.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDosage Calculations:\u003c\/strong\u003e Confirm dose using 62.5 mg per 5 mL concentration; do not exceed recommended volume. Use the exact volume prescribed (e.g. 10 mL = 125 mg elemental iron).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eDosage and Administration\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdult Patients:\u003c\/strong\u003e The typical repletion dose is \u003cstrong\u003e125 mg elemental iron (10 mL)\u003c\/strong\u003e per hemodialysis session. This dose may be given diluted over 1 hour or slow IV push (12.5 mg\/min). For most patients, a total course of about 1,000 mg (eight 125 mg doses) over successive dialysis visits is needed to correct anemia levels. After iron stores are replete, maintenance doses (e.g. 125 mg monthly) may be used to keep hemoglobin and serum ferritin in target range.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePediatric Patients (≥6 years):\u003c\/strong\u003e Dose is \u003cstrong\u003e1.5 mg\/kg of elemental iron\u003c\/strong\u003e (0.12 mL\/kg), up to 125 mg, given diluted in 25 mL NS over 1 hour per dialysis. Do not exceed 125 mg per dose. Multiple doses over 8 sessions are typically required for full repletion. Safety\/efficacy in children \u0026lt;6 years not established.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdministration Details:\u003c\/strong\u003e Administer during or immediately after dialysis session. Do \u003cstrong\u003enot\u003c\/strong\u003e combine the injection with parenteral nutrition or other IV drugs. Always use the vial solution as soon as drawn and complete infusion before the end of dialysis hour.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eDrug Interactions\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eNo Known Major Interactions:\u003c\/strong\u003e Formal drug–interaction studies have not identified significant interactions with sodium ferric gluconate infusion. Iron infusion bypasses the gut, so oral absorption interactions (with tetracyclines, fluoroquinolones, levothyroxine, etc.) are minimized, but it is still advisable to \u003cem\u003einform the physician of all medications and supplements\u003c\/em\u003e being taken.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCoadministration Caution:\u003c\/strong\u003e Calcium, magnesium, antacids, and certain antibiotics can bind iron if given orally; these are usually spaced apart when oral iron is used. With IV iron, this is less of a concern, but check labels of each medication. In all cases, ensure compatibility; \u003cem\u003edo not mix in the same IV line\u003c\/em\u003e with anything other than normal saline.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eErythropoietin Agents:\u003c\/strong\u003e No direct negative interaction – in fact, sodium ferric gluconate is intended to be used with epoetin (EPO) to achieve better anemia control. Continue monitoring blood counts and iron studies to adjust doses of erythropoiesis-stimulating agents accordingly.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eSide Effects\u003c\/h2\u003e\n\u003cp\u003eCommon side effects are generally mild to moderate and may include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGastrointestinal discomfort:\u003c\/strong\u003e nausea, vomiting, or diarrhea. These may occur during or shortly after infusion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInjection site reactions:\u003c\/strong\u003e pain, burning, swelling, or irritation at the site of IV infusion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFlushing or Hypotension:\u003c\/strong\u003e transient low blood pressure (hypotension) can cause dizziness, faintness, or headache. Conversely, some patients may experience transient hypertension (rise in blood pressure) after infusion. Vital signs should be monitored during administration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMusculoskeletal:\u003c\/strong\u003e cramps or pain in legs or abdomen.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRespiratory\/General:\u003c\/strong\u003e shortness of breath, chest pain, general malaise, or unusual sensations (e.g. headache, fatigue, rash).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAllergic Reactions:\u003c\/strong\u003e Itching, hives, swelling, or asthma-like symptoms can occur, typically during the infusion. \u003cem\u003eSerious\u003c\/em\u003e (rare): anaphylaxis (life-threatening allergic reaction) is possible. Symptoms include difficulty breathing, throat tightness, rapid heartbeat, or severe hypotension – \u003cstrong\u003eseek emergency care immediately\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOther:\u003c\/strong\u003e Back pain, leg pain, or fever have been reported. Report any unexpected symptoms to a healthcare provider.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf severe side effects occur (e.g. passing out, chest pain, trouble breathing, confusion), stop the infusion and get medical help right away. For any concerns during infusion, notify medical staff immediately.\u003c\/p\u003e\n\u003ch2\u003eWarnings and Precautions\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypersensitivity (Allergy\/Anaphylaxis):\u003c\/strong\u003e Serious allergic reactions can occur, especially on first dose. \u003cem\u003eInfuse only in a setting equipped for resuscitation and monitor patient closely for at least 30 minutes after infusion completion.\u003c\/em\u003e Discontinue if signs of anaphylaxis (rash, bronchospasm, hypotension) appear.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypotension:\u003c\/strong\u003e Sodium ferric gluconate may cause drops in blood pressure. Infuse slowly and monitor. If hypotension occurs, slow or stop the infusion and manage supportively (e.g. IV fluids) as needed.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIron Overload:\u003c\/strong\u003e Over-treatment can lead to iron overload and related organ damage. \u003cstrong\u003eDo not use\u003c\/strong\u003e in patients with known hemosiderosis, hemochromatosis, or other iron storage disorders. Before each dose, check hemoglobin, ferritin, and TSAT. Do not exceed recommended dosing unless guided by lab values and specialist advice.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eContraindications:\u003c\/strong\u003e Do not give to anyone with a history of serious allergic reaction to iron gluconate or any component of the injection. Also avoid use in anemia not caused by iron deficiency (e.g. hemolytic anemia, bone marrow disorders) as it offers no benefit and poses risk.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeonates and Pediatrics:\u003c\/strong\u003e Contains benzyl alcohol; \u003cstrong\u003enot for use in neonates or infants\u003c\/strong\u003e (risk of “gasping syndrome”). Safety in children under 6 yrs is not established. Use with caution and dosing by weight in older children.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePregnancy and Lactation:\u003c\/strong\u003e Use only if clearly needed during pregnancy. Risk of hypersensitivity to fetus is unknown. Iron is essential in pregnancy, but the decision should balance maternal benefit vs. potential fetal risk. Not known if excreted in breast milk; discuss with physician before breastfeeding.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOther Precautions:\u003c\/strong\u003e Store properly; discard if frozen or contaminated. Monitor iron levels periodically; resume maintenance treatment only when iron stores fall or anemia recurs. Patients with acute or chronic infections should be monitored closely, as iron can theoretically promote bacterial growth. Avoid overdose – fatal iron toxicity can occur in children if accidentally ingested.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eWARNING:\u003c\/strong\u003e \u003cem\u003eThis is a potent prescription iron medication. Use only under medical supervision with appropriate monitoring.\u003c\/em\u003e\u003c\/p\u003e","brand":"Hikma Injectables","offers":[{"title":"Default Title","offer_id":53924027466096,"sku":"00143957010","price":369.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Sodium-Ferric-Gluconate-Complex-in-Sucrose-Injectio.jpg?v=1781789901"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/collections\/Iron-Sucrose-Injection-100-mg-Elemental-Iron-per-5-mL-Single-Dose.jpg?v=1779210689","url":"https:\/\/www.mountainside-medical.com\/collections\/iron-sucrose-injections\/iron+iron-supplement+76329-9200-01.oembed","provider":"Mountainside Medical","version":"1.0","type":"link"}